Logo Jan Blom

Oncologisch onderzoek.nl

Zoek in alle tags

Meerdere komma gescheiden tags zullen onderling worden beschouwd als logisch AND. Je kan ook een ; gebruiken for logisch OR. AND heeft prioriteit over OR en je kan geen haakjes gebruiken om logische groepen te definieeren. Sterretje * binnen een tag zal als een masker voor elk mogelijk karakter.

'gunstig hoog-risico' “one thousand HER2 patients” project [11C] docetaxel [18F]paclitaxel %FT 10-year recurrence 15-hydroxyprostaglandinedehydrogenase 15-PGDH 16K PRIL 16q23 1703-studie 18F-FDG opname 1p 19q co-deleted oligodendroglioma 21-gen recurrence score assay 21-gene expression assay 21-gene recurrence score 25-hydroxyvitamin D 27-hydroxycholesterol 28-year risk of lung cancer 321GO 3D brachytherapy 3DCRT 4EVER trial 4L lymph node dissection 5-ARIs 5-FU 5α-reductase inhibitors 70-GS 8-OHdG 90101 CREATE-studie 90YIT 91-maands update van CALGB 100104-studie A.R.R.O.W-studie A041202 study AAC AACR AACR 2015 AACR Academy AAML0531 trial AAP ABCSG 8A trial ABCSG-18 study abemaciclib plus fulvestrant for MBC Abi Race studie abirateron abiraterone abiraterone for prostate cancer ablatieve behandeling abnormale peritoneale cytologie ABOUND.2L+ study ABSI ABSOLUTE absolute dense area absoluut neutrofielgetal ABT-199 ABTC ABVD ACC accelerated partial breast irradiation ACCRU study SC-1603 accrual ACE ACE study ACE-LY-004 studie ACES acetaminophen acne ACOSOG Z0011 ACP statement acquired resistance to osimertinib acraal melanoom ACRIN 6686-studie ACT Act.In.Sarc study actieve surveillance ACTIM actinisch carcinoom active melanoma brain metastases active surveillance activering immuunsysteem ACTs acupuncture for aromatase inhibitor-related joint pain acute kidney injury acute leukemie acute lymfoblastische leukemie acute myeloid leukemia acute myeloïde leukemie acute promyelocytische leukemie acute promyeolcytische leukemie acute toxicity AD-risico ADAM-studie ADAM8 ADAMTS-mutaties ADAPT-studie adaptive randomization ADC versus SCC ADCs additional cytogenetic abnormalities ADEBAR ademanalyse ademtest adenocarcinoma of the small intestine adenocarcinoom adenoma detection rate ADH adherence adherene to adjuvant endocrine therapy adherentie adherentie AET adherentie orale chemotherapie adipositas adjuvant bevacizumab adjuvant capecitabine adjuvant care adjuvant chemotherapy adjuvant chemotherapy regimens adjuvant CRT adjuvant denosumab adjuvant erlotinib for early-stage NSCLC adjuvant FOLFIRINOX versus gemcitabine adjuvant imatinib adjuvant ipilimumab adjuvant multimodality therapy adjuvant radiation therapy adjuvant radiotherapy adjuvant RT adjuvant S-1 adjuvant S-1 with or without docetaxel adjuvant therapy adjuvant trastuzumab adjuvant trastuzumab duration adjuvant treatment ADJUVANT-studie adjuvante chemotherapie adjuvante CRT adjuvante HER2-remming adjuvante hormoontherapie adjuvante systemische therapie ADMIRAL study ADNEX ado-trastuzumab emtansine adolescent and young adult adolescent and young adult HL adolescent overweigh or obesity adolescents and young adults adoptive T-cell therapy ADR adrenocortical carcinoma ADT ADT risk of depression adult height adult survivors of childhood ALL adult survivors of childhood cancer adult T-cell leukemia lymphoma adult type granulosa cell tumors of the ovary adult weight gain advanced anal squamous cell carcinoma advanced biliary tract cancer advanced biliary tract cancers advanced breast cancer advanced cancer advanced EGFR-positive non-squamous NSCLC advanced endometrial cancer advanced esophageal cancer advanced gastric cancer advanced gastroesophageal cancer advanced germ cell tumors advanced HCC advanced hepatocellular carcinoma advanced HN CSCC advanced HNSCC advanced Hodgkin lymphoma advanced indolent lymphoma advanced melanoma advanced Merkel cell carcinoma advanced mucosal melanoma advanced non-clear cell RCC advanced non-clear-cell RCC advanced non-small cell lung cancer advanced NSCLC advanced or metastatic colorectal cancer advanced or refractory desmoid tumors advanced ovarian cancer advanced ovarian carcinoma advanced ovarium neoplasms advanced pancreatic cancer advanced PDAC advanced prostate cancer advanced pulmonary sarcomatoid carcinoma advanced RCC advanced recurrent ovarian cancer advanced renal cell carcinoma advanced sarcoma advanced solid cancers advanced solid malignancies advanced solid tumors advanced squamous NSCLC advanced triple-negative breast cancer advanced urothelial cancer advanced wild-type BRAF melanoma advanced-stage cancer advanced-stage Hodgkin’s lymphoma adverse events adverse mental health outcomes aerobe inspanning aerobic and resistance exercise aerobic exercise during chemotherapy afatinib afatinib versus methotrexaat AFFIRM AFFIRM-studie aflibercept AFUGEM GERCOR AGC age age at diagnosis age disparities age-specific BMI agent orange AGES-Reykjavik study aggressive lymphoma AGITG MAX study AGO-OVAR 16-studie agressieve fibromatose agressive squamous cell carcinoma AGRICAN-studie aGVHD AHEP0731 study AHL2011 study AHOD1221 study AI AI-therapie AIC AIO-FLOT3 studie AJCC CSM-8 AL-amyloïdose ALBI ALCANZA-studie ALCL alcohol alcohol and tobacco consumption alcohol consumption alcohol intake alcoholconsumptie alcoholgebruik ALCYONE-studie aldoxorubicine alectinib alectinib versus crizotinib ALEX study ALEX-studie ALFA-0701 trial ALiCCS studie ALiCCS study ALiCCS-studie alisertib ALK-positive non-small cell lung cancer ALK-positive NSCLC ALK-rearranged NSCLC ALK-remmer ALK1 alkaline phosphatase alkylerende chemotherapie ALL Alliance A091401-studie Alliance N0572-studie ALLIVE-studie allo-BMT allo-HSCT allo-HST allogene hematopoïetische stamceltransplantatie allogene stamceltransplantatie allogeneic BMT in childhood allogeneic hematopietic cell transplantation allogeneic hematopoietic cell transplant allogeneic hematopoietic cell transplantation allogeneic HSCT alloHCT alloHSCT alloSCT ALND alopecie alpelisib alpelisib plus fulvestrant ALTA-1L ALTA-studie ALTER 0303 study ALTERNATIVE-studie ALUR-studie alveolar soft-part sarcoma alvleesklierkanker AM Amara West AMD American Association for Cancer Research American Cancer Society richtljnen AMG 337 AMH AML AML MDS AML-relapse after allo-HCT AML-risico AML17-studie AMPK variant AMPK-route AMPLE-2 study amrubicine analgesic use analgesics analgetica analyse AZURE-studie analyse binnen PICCOLO-studie analyse CheckMate 205-studie analyse COG AAML 1031 analyse CROSS-studie analyse fase 3-studie CALGB 40503 analyse fase 3-studie GeparQuinto analyse MA.27-studie analyse NORDIC-VII studie analyse STAMPEDE-studie Analyse van CheckMate 066 en CheckMate 067 analyse van fase 3-studie CAO ARO AIO-04 analyse van STAMPEDE-studie anaplastic large-cell lymphoma anaplastisch grootcellig lymfoom anaplastisch schildkliercarcinoom anastrozol anastrozole and HIV infection and rituximab and time already survived androgeendeprivatie androgeenreceptor androgeensuppressie androgen concentrations in prepubertal girls androgen deprivation therapy androgen deprivation therapy for prostate cancer androgen receptor expression androgen receptor signaling inhibitor anesthesia aneuploïdie angiogenese angiosarcomen angiosarcoom angiotensin converting enzyme inhibitors ANGPT2 anlotinib anlotinib versus sunitinib anoikis-resistentie anorexia nervosa anorexie anosmin-1 antacida anthracycline chemotherapie anthracyclines anthracylcines anti-angiogene middelen anti-angiogenese anti-CTLA-4 plus anti-PD-1 blockade anti-Hu anti-humaan T-lymfocyt immunoglobuline anti-PD-(L)1 therapy anti-PD-1 antibodies plus RT anti-PD-1 L1 anti-PD-1 related pneumonitis anti-PD-1 therapy anti-PD-1 therapy for advanced melanoma Anti-T-lymfocten globuline anti-VEGF therapie anti-VGEF therapie antiangiogenese antibodies antibody-drug-conjugates anticoagulatie antihypertensive drugs antiogeneseresistentie antioxidant supplements antioxidanten antioxidants antithymocytenglobuline antitumor-werkzaamheid van bisfosfonaten antiviral treatment anus squameus celcarcinoom anuscarcinoom anuskanker AO AOA apalutamide apatinib apatinib plus oral etoposide aPC APHINITY-studie API-AI apixaban APL apoptose appendixcarcinoom aprepitant APT trial AR-expression AR-remming AR-V7 ARAMIS study ARCAD ARCAGE-studie aRCC ARCHER 1050 ARCHER 1050-studie ARIC-studie ARIEL3-studie Aristotle study ARMD aRMS aromatase inibitor-induced adverse effects aromataseremmer aromataseremmers array comparative genomic hybridization ARROW study ARRY-380 arseentrioxide arsenicum ART ART-gerichte behandeling arterial thromboembolism preceding cancer diagnosis artificial intelligence ARTIS study ARTIST 2 study artralgie ARv567es ASCC ASCEND-2 ASCEND-5 ASCEND-5 studie ascites ASCO ASCO 2016 ASCT ASCT versus maintenance chemotherapy consolidation ASH 2015 Ashkenazi Jewish ancestry ASILs ASPECCT AspECT study ASPIRE-studie aspirin aspirin NSAID use aspirine aspirine NSAIDs aspirineprofylaxe ASPS assessment of lung cancer risk Assisted reproduction assisted reproductive technology associatie diabetes en kanker association between PFS and QOL association of cutaneous toxic effects with outcomes association with survival AST astma ASTRO 2015 ASTRO 2016 asymptomatic brain metastases asymptomatic WM ATBC Study ATE atezolizumab atezolizumab plus bevacizumab atezolizumab plus nab-paclitaxel ATL ATLANTIC-studie ATM ATOM trial atopie ATR-blockers atriumfibrilleren ATRTs ATTRACTION-2 studie atypical bronchopulmonary carcinoids atypical squamous cell of undetermined signifance atypical squamous cells of undetermined significance atypisch meningioom atypische ductale hyperplasie atypische hyperplasie Atypische teratoïde rhabdoïde tumor atypische teratoïde rhabdoïde tumoren AUGMENT study AURA AURA-studie AURA-substudie AURA2 AURA3 AURA3 study AURA3-studie AURELIA AURELIA-studie AURELIA-substudie Aurora A aurora kinase A inhibition Australian Melanoma Family Study auto-immuunziekten autofagie autoHCT autoHSCT autoimmune disease autologe stamceltransplantatie autologous stem cell transplantation AVAglio AVAST-M study AVAST-M trial avastin avelumab avelumab plus axitinib AVERT study AVERT trial axicabtagene ciloleucel axillaire lymfeklierdissectie axillaire radiotherapie axillaire status axillaire ultrasound axillary dissection axitinib axitinib plus pembrolizumab AYA cancer AYA cancer survivors AYA-maligniteiten AYAs AYAs versus older adults AZ9291 azacitidine B-cel activering B-cel lymfoom B-cel maligniteiten B-cel precursor-ALL B-cellymfoom B-precursos ALL B-progenitor acute lymphoblastic leukemia baarmoederhalskanker BALLET-studie bariatrische chirurgie Barrett esophagus Barrett slokdarm Barrett-slokdarm Barrett's esophagus Barrett's slokdarm Barrett’s oesophagus basaalcelcarcinoom basal-like mammacarcinoom Baselga bassi BAT bb2121 BBB BBD BBD-BC BCBM BCC BCCs BCCSS BCIN+ BCIS Bcl-2 BCL2 expression BCNU BCP-ALL BCS BCS for N2 N3 disease BCT versus mastectomie BCT vs MAST BEACON CRC study BEACON-studie subgroep-analyse BEAT Cancer interventie BEBYP-studie beeld-geleide brachytherapie beeldvorming beenmergevaluatie beha belangenconflicten belinostat BELLE-2 studie BELOB bendamustine benign biopsy rate benign solid tumors benigne borstziekte benzeen benzodiazepine BEP BERIL-1 bestraling beta-arrestin-1 BETA-Text bètablokkers between-hospital variation bevaciumzab bevacizumab bevacizumab biosimilar bevacizumab preconditionering voor chemotherapie BEVZ92 BFORE-studie BGJ398 bhatia BI-ALCL BIA ALCL BIDOC-studie BIG 1-01 BIG 1-98 bijnierschorscarcinoom bijniertumoren bijwerkingen bilaterale risicoreducerende mastectomie BILCAP study BILCAP-studie biliary tract cancer BIND-014 Bing-Neel syndrome binimetinib biochemisch recidief biological aging biologische beschikbaarheid biomarker biomarker voor respons op bevacizumab biomarkeranalyse ASPECCT-studie biomarkers biopsie schildwachtklier BIRCH-studie birinapant birth defects birth order bisfosfonaat bisfosfonaten blaascarcinoom blaaskanker black race black versus nonblack men black versus white women Black Women's Health Study Black Women’s Health Study bladder cancer bladder cancer in postmenopausal women bladder cancer VI-RADS score bleeding risk bleomycin-related pulmonary toxicity bleomycine blinatumomab blinded double reading bloedgluocse bloeding bloedkanker bloedlipiden bloedtest colorectaalcarcinoom Blood or Marrow Transplant Survivor Study-2 blood tests blood tumor mutational burden bloodstream infections BLU-667 BM BMD BMI BMM BO body composition body composition and cardiovascular events body fat body fat distribution body fat percentage body mass index body shape trajectory Boekel BOLERO-1 BOLERO-2 bone loss in younger breast cancer patients bone marrow biopsy bone metastases bone-only metastasis bone-targeted agents borderline ovariumtumor borderline resectable pancreatic cancer Borealis-1 studie Borealis-2 studie borstbiopsie borstchirurgie borstdichtheid borstimplantaat borstkanker borstkanker bij mannen borstkankerpreventie borstkankerscreening borstkankerscreening oudere vrouwen borstkankersterfte borstparende chirurgie borstreconstructie borstreconstructie na mastectomie borstsparende chirurgie borsttomosynthese borstvoeding bortezomib bortezomib plus chemotherapy bortezomib plus rituximab maintenance BOSS cohort bot-SPNs boteffect botmetastasen botmetastasen van mammacarcinoom botmetastasering botmicrometastasen botox botpijn botsarcoom bovenste-luchtwegkanker BP-RMS BPDCN BPH BPM BPs BR BRAC1 2-mutation brachytherapie BRAF BRAF 594 en 596 mutaties BRAF 600 wild type melanoom BRAF mutation BRAF plus MEK inhibition BRAF V600-mutated mNSCLC BRAF V600-mutated NSCLC BRAF V600E BRAF V600E mCRC BRAF wild-type advanced melanoma BRAF-genfusies BRAF-mutant melanoma BRAF-mutated malignancies BRAF-mutated melanoma BRAF-remmer BRAF-remmers BRAF-remming BRAF-V600E brain imaging brain metastases brain metastases nivolumab plus ipilimumab brain metastasis brain tumors brain volume brain-metastatic lung cancer BRCA BRCA mutation carriers with breast cancer BRCA-mutatie BRCA1 BRCA1 2 germline mutations BRCA1 2 mutation BRCA1 2 mutations BRCA1 2 variants BRCA1 2-mutatie BRCA1 2-mutaties BRCA1 2-mutations BRCA1 and BRCA2 mutations BRCA1 mutation BRCA1-mutatie BRCA2 BRCA2-associated breast cancer BRCA2-mutaties breast and lung cancer mortality in women breast and prostate cancer breast cancer breast cancer bone metastasis breast cancer brain metastases breast cancer brain metastasis breast cancer chemotherapy breast cancer diagnosis breast cancer family history breast cancer in childhood cancer survivors breast cancer in high-risk women breast cancer in young women breast cancer leptomeningeal disease breast cancer metastases breast cancer metastatic recurrence breast cancer mortality breast cancer outcomes breast cancer ovarium cancer predisposition genes breast cancer risk breast cancer screening breast cancer screening in average-risk women breast cancer subtype breast cancer subtypes breast cancer surgery breast cancer survival breast cancer survivors breast cancer survivorship breast cancer-related fatigue breast cancer-specific mortality breast compression breast desmoid tumor management in France breast intraepithelial neoplasia recurrence breast symptoms breast-conserving surgery brentuximab vedotin brentuximab verdotin brigatinib BRIM-3 studie BRIM8-studie British Childhood Cancer Survivor Study Broad-based genomic sequencing BRPC BRRM bruton's tyrosine kinase BTC BTK Burkitt's lymfoom busulfan plus fludarabine busulfan plus melphalan conditioning BV BV plus AVD BVD-523 C SCANS studie C-486 C-ALCL C-ion RT C-reactive protein C-TASK FORCE studie CA-125 CA180-226 studie CA19-9 CA209-003 studie CA301 study CABARET-studie cabazitaxel CABOSUN cabozantinib cabozantinib versus everolimus CAD CADC CADM1 MAL-methylering cafeïne caffeïne CAG-repeat CAIRO3 calcitonin receptor-like calcium calcium supplementation calciuminname calculated tumor area CALGB 50604 CALGB 89803-studie CALGB Alliance 140503 CALGB SWOG 80405 study CALOR-studie caloric restriction CAM camrelizumab cancer cancer burden in patients with sleep apnea cancer clinical trial participants cancer detection rate cancer diagnosis cancer diagnosis in primary care cancer driver genes cancer drugs approved based on response rate cancer history cancer in solid organ transplantation recipients cancer incidence and mortality cancer mortality Cancer of unknown rimary cancer patients cancer patients treated with anticoagulation cancer prevention cancer recurrence cancer risk cancer risk after hematuria diagnosis cancer risk in children cancer risk in children and adolescents cancer screening cancer surgical procedures cancer survivors cancer susceptibility genes cancer-related cognitive impairment cancer-related fatigue cancer-specific mortality cancer-testis antigens canine lung cancer detection cannabigerol cannabis CanSNET-studie CANTO trial CAO ARO AIO-04 study CAP-studie capecitabine capecitabine versus observation capivasertib for tumors with AKT mutations CAPP-Seq CAPRI-GOIM CAPRICE CAR T-cell therapy CAR T-cellen voor solide tumoren CAR T-celtherapie CAR-T celtherapie carbazitaxel carbon ion RT carboplatin with radiotherapy carboplatine carcinoïd tumoren cardiac events cardiac safety cardiale disfunctie cardiale toxiciteit cardiale veiligheid cardiorespiratorische fitheid cardiorespiratory fitness cardiotoxiciteit cardiotoxiciteit anthracylines cardiotoxiciteit chemotherapie cardiotoxicity cardiovasculair risico cardiovasculaire toxiciteit cardiovascular diseasse cardiovascular risk carfilzomib CARMENA study CARMENA-studie carmustine Carolina Breast Cancer Study carotenoïden carpaal-tunnelsyndroom CARTS study CASPS study CASR CASSINI study CASSIOPEIA study CASTOR and POLLUX age subgroup analysis castratieresistent prostaatcarcinoom castration-resistant prostate cancer CATCH catch-up HPV-vaccination CATNON-studie catumaxomab cause of death CBC CBC risk CBC-risico CBTRUS CBTS cc mRCC CC-223 CCEC CCNE1 expression CCR7 ccRCC ccRCC brain metastases CCRT CCSS CD19 CAR-T cell therapy CD47 blockade plus rituximab CD8+ T cell infiltration CDK4 6-remming CDKN2C CDS CDX-110 CDX2 CEA CEA-specifieke T-cel respons cediranib CEGT celecoxib CELESTIAL trial cell-free urine cellulaire immuuntherapie cellular immune activation CelTIL-score celvrij circulerend tumor DNA central adiposity centrale adipositas cerebellopontine angle tumors cerebrospinale vloeistof ceritinib cervical cancer cervical cancer screening cervical HPV-testing cervical neoplasia cervical screening cervicale glandulaire neoplasie cervicale intra-epitheliale neoplasie graad 3 cervicale intraepitheliale neoplasie cervicale-slokdarmkanker cervixcarcinoom cervixcarcinoomscreening cervixconisatie cervixkanker cervixkankerscreening cervixlaesies CESM CETSA cetuximab cetuximab-IRDye800 cetuximab-related infusion reactions cetuximab-resistentie CF-WBI cfDNA CGC cGVHD ch CHAARTED-analyse CHAARTED-studie change in serum uric acid level change of breast cancer subtype during neoadjuvant chemotherapy Charlson-score CHD CheckMate 012 CheckMate 016-studie CheckMate 017 en 057 CheckMate 017 en CheckMate 057 CheckMate 017-studie CheckMate 025 CheckMate 026-studie CheckMate 032 study CheckMate 037 CheckMate 040 CheckMate 064 CheckMate 066 CheckMate 066 study CheckMate 067 CheckMate 069 CheckMate 069 066 en 067 CheckMate 141 CheckMate 141-studie CheckMate 142 CheckMate 204 study CheckMate 205 study CheckMate 214 CheckMate 227-studie CheckMate 238-studie CheckMate 275 CheckMate 370-studie CheckMate 384 study CheckMate 511 trial CheckMate 568 CheckMate-032 study CheckMate-142 checkpoint blockade immunotherapy checkpoint inhibitor therapy checkpoint kinases CHEK2 1100delC CHEK2 germline pathogenic variants CHEK2-mutaties CHEK2*1100delC chemerin plasma concentration chemobrain chemoimmunotherapy chemopreventie mammacarcinoom chemopreventie van mammacarcinoom chemoprevention with low-dose aspirin chemoradiotherapie chemorefractory metastatic colorectal cancer Chemoresistentie chemosensitizatie chemotherapie chemotherapie tijdens zwangerschap chemotherapie-geïnduceerd ovariumfalen chemotherapie-geïnduceerd POF chemotherapie-geïnduceerde febriele neutropenie chemotherapie-geïnduceerde misselijkheid en braken chemotherapy chemotherapy after colorectal cancer liver metastasectomy chemotherapy alone versus combined modality therapy chemotherapy benefit chemotherapy demands chemotherapy plus ponatinib chemotherapy regimens chemotherapy response score chemotherapy versus observation chemotherapy-free treatment chemotherapy-induced nausea and vomiting chemotherapy-induced peripheral neuropathy chemotherapy-related cognitive impairment chemotherapy-related hematological toxicity CHF CHHiP-studie childbearing potential childbirth childhood ALL childhood B-ALL childhood brain tumors childhood cancer Childhood Cancer Survivor Study childhood cancer survivors childhood leukemia childhood leukemia risk childhood leukemia; maternal hormonal contraception use children children and AYAs with cancer Children’s Oncology Group Children’s Oncology Group Study AALL03N1 chimeric antigen receptor CHIP chirurgie cHL cHL in young patients cholangiocarcinoma cholangiocarcinoom cholecystitis chondrosarcoma chondrosarcoom CHOP chordoma chordoom chromische lymfocytische leukemie chromocolonoscopy versus white-light colonoscopy chromosoom 21 chromosoominstabiliteit chromothripisis chronic health conditions chronic lymphocytic leukemia chronic pain chronic phase CML chronisch graft-versus-host disease chronische fase CML Chronische fase-CML chronische lymfatische leukemie chronische lymfocytische leukemie chronische lymfoide leukemie chronische myelomonocytische leukemie Chronos-1 chubb chyleuze ascites CIA cilengitide CIMP CIN CIN 3 CIN2 3 CIN2+ detection CINP CINV CIO CIOD CIPN circadiaan ritme circulating DNA circulating HPV DNA circulating sex hormone levels circulating tumor cells circulating tumor DNA circulerend DNA circulerend tumor-DNA circulerende tumorcellen circulerende tumorcellen; detectie nieuwe mutaties circulerende vetzuren CIRT CISIG cisplatin cisplatine citrusfruit cixutumumab CLARITY study claudine 18.2 CLEAR Clevers clinical and genomic risk clinical characteristics and outcomes clinical features for prediction of survival clinical meaningful outcomes clinical trial enrollment clinical trial participation clinical trials clinically N2 non-small cell lung cancer CLL CLL 2007 SA-studie CLL in younger patients CLL with coexisting conditions CLL-IPI CLL10 CLL2-BAG study CLLM1-studie CLM CLND clofarabine CLOG1302-studie clomid clomifeen clomifeencitraat Clozel CME CML CML-BP CML-CP CML-studie IV CMM CMML CMSs CMV-viremie CN-AML CNAs CNBSS CNS efficacy CNS metastases CNS metastasis CNS response CNS-DLBCL CNS-lymfoom CNS-metastasen CNS-recidief HER2-tumoren CNS-tumoren CNS-tumoren; impact van behandelcentrum cobas cobimetinib COBRA study COBRA-score coBRIM-studie coffee intake COG AALL0434 COG AALL0622-studie COG AAML0631-studie COG AREN0533-studie COG-studie AAML0531 COG-studie AREN0532 cognitief functioneren cognitieve disfunctie cognitieve klachten cognitieve veranderingen na chemotherapie cognition cognitive and neurobehavioral impairment cognitive performance colectomie collider stratification bias COLOFOL-studie Cologuard colon cancer colon cancer drug metabolism Colon Cancer Family Registry colon cancer peritoneal recurrence colon-NET coloncarcinogenese coloncarcinoom colonkanker colonoscopie colonoscopy-based CRC screening colorectaakanker colorectaaladenomen colorectaaladenoom colorectaalcarcinoom colorectaalkanker colorectaalkankerscreening colorectaalneoplasie colorectaalpoliepen colorectal colorectal adenomas colorectal cancer colorectal cancer molecular subtypes colorectal cancer mortality colorectal cancer precursors colorectal carcinogenesis colorectal liver metastases colorectale chirurgie colorectale levermetastasen colorectale neoplasie coloscopie COLUMBUS trial COMBI-AD studie COMBI-AD study COMBI-d studie COMBI-MB studie COMBI-v CombiDT combined BRAF- and MEK-inhibition plus PD-1 blockade combined effect of breast density and BMI combined modality treatment combined-modality therapy community jury comorbiditeiten comorbidities comparative safety of ICIs comparison Hong Kong and USA complementaire en alternatieve behandelingen complementary and alternative medications complementary medicine COMPLETE study complex karyotype COMPOSE-studies computationele pathologie Computer-geassisteerde chirurgie concomitant mutations concomitant use CONCORD-2 CONCORD-3 concurrent chemoradiotherapy conditionele ziektevrije overleving CONDOR trial congenital heart disease congestive heart failure conjunctival melanoma CONKO-004 connexine 30 consensus molecular subtypes conservative management CONSIGN consolidation with WBRT or stem-cell transplantation consoliderende radiotherapie Consomic Xenograft Model contemporary hormonal contraception CONTINUUM-studie contralateraal mammacarcinoom contralateral breast cancer contralaterale borstkanker contralaterale mastectomie contralaterale profylactische mastectomie CONVERT-studie CONVINCE-studie COPD copy number alteration screening copy number loss corpus uteri cancer corticosteroïden corticosteroids cost-effectiveness cost-effectiveness of CAR T-cell therapy cost-effectiveness of intraoperative MRI Costa RIca Costa Rica HPV Vaccine Trial cotinine coxibs CP-CML CP-genen CpG-B CPI-613 CPIs CPM CPPT CPX-351 CRA craniotomie CRBSI crc CRC detection CRC diagnosis CRC incidence CRC intrinsic subtypes CRC liver metastases CRC risk CRC stage distribution CRC survival CRC survivors CRC-biomarkers CRC-diagnose CRC-risico CRC-screening CRCD CREATE-studie crenigacestat CRF cribriform groeipatroon CRICKET trial crizotinib CRLM CRLX101 CRN CROSS CRP CRP-niveau CRPC CRPC with bone metastases CRS CRS HIPEC CRS-207 CRS-HIPEC cost effectiveness CRT CRT versus CT CSCC CSCCs CSM CT CT examinations CT lung cancer screening CT-longkankerscreening CT-P10 CT-screening longkanker cT1-2N0 breast cancer cT1T2No OTSCC CTCAE CTCL CTCs ctDNA CTLA-4 CTLA-4 blokkade CTLC CTP CUDC-907 CUETO CUP curatie current or former smoking cutaan squameus celcarcinoom cutaan squameus celcarcinoom van hoofd en hals cutaan T-cel lymfoom cutane bijwerkingen cutaneous adverse events cutaneous BCC cutaneous HNSCC with regional lymph node metastasis cutaneous malignant melanoma cutaneous squamous cell carcinoma CUX1-ALK rearrangement CVD CVSS-studie CXB CXM cycline D1 cyclofosfamide cyclophosphamide CYP3A cyproteronacetaat cyramza cystectomie cytarabine CYTO-CHIP study cytogenetisch normaal AML cytokines cytology testing cytoreductive surgery D-2-hydroxyglutaraat D-Rd versus Rd D-VCd DA-EPOCH-R versus R-CHOP dabrafenib dabrafenib plus trametinib dabrefenib plus trametinib dacomitinib DADI DAFI daily aspirin daratumumab darm-microbioom darm-stamcellen darmflora darmkanker darolutamide DART S1609 neuroendocrine cohort DART-studie dasatinib DATA-studie David A. Karnofsky Memorial Award and Lecture davoli DAWN-studie DAWT DBCG 07-READ studie DBMS DC-CIK DCE-MRI DCF chemotherapy DCIS DCIS before age 50 years DCIS grading DCOG-LATER cohort DCOG-LATER cohort study DCOG-LATER studie dd-chemotherapie DDCT de novo stage IV HER2-positive MBC De-ESCALaTE HPV study de-escalation of TKIs Debio0932 Decipher decision support system decitabine deep learning definitive radiotherapy degarelix DEL delirium dementia Denemarken denosumab dentaal trauma depressie depression depth of response dermatofibrosarcoma protuberans desmoïd DESTINY study DESTINY-studie detectie Detectie borstkanker detectie colorectaalkanker detecting genomic biomarkers in plasma versus tissue detection advanced neoplasia detection bias detection early-stage OPSCC detection of CTCs during follow-up detection of invasion of detrusor muscle detection of mutations in ctDNA detection of non-index lesions detection of prostate cancer detection of relapse determinants of breast cancer risk determinants of optimal adjuvant therapy determinants of tumor cell PD-L1 expression dexamethason dexanethasone dexrazoxane DFP-10917 DHA DHAP DHL diabetes diabetes and cancer risk diabetes mellitus diagnose longcarcinoom DICER1 pathogenic variants diet qualiity diet quality dietary carbohydrate quality and human health dietary fiber dietary intake dietary supplement use differences in treatment outcomes differential ribosome measurements of codon reading differentiated thyroid cancer difficult patients diffuse large B cell lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma-specific mortality Diffuse optical spectroscopic imaging diffuse type TGCT diffuse-type giant cell tumor diffuus grootcellig B-cel lymfoom diffuus intrinsiek ponsglioom digital breast tomosynthesis digital breast tomosythesis digital screening mammografie DigniCap digoxine DII DIPG DIPG-BATS studie direct-acting antivirals discontinuation imatinib for CML in children discontinuation of anti-PD-1 antibody therapy disease-free survival disparities by race ethnicity and age distal cholangiocarcinoma distal rectal cancer distale pancreatectomie distant disease-specific survival distant metastatic breast cancer distant recurrence of breast cancer distress Distress Thermometer DLBCL DMFS dMMR CC dMMR PDAC DN DNA damage immune response DNA promoter-hypermethylering DNA-methylering DNA-test DNMT3A-mutatie docetaxel documentaire doelgerichte behandeling donor clonal hematopoiesis DoR dormancy-genen dosisescalatie DOT1L double expressor DLBCL DOVIGIST-studie doxorubicin delivery from ultrasound-triggered liposomes doxorubicine DPYD genotyping DPYD*2A variant carrying cancer patients droge mond droplet digital PCR drug response predictor drug-drug interactions DSMM XI-studie DSRCT dt-GCT DTC DTCs ductaal carcinoom in situ ductal carcinoma in situ dunne-darmadenocarcinoom dunne-darmneoplasie DUO study duration of adjuvant trastuzumab duration of response durvalumab dutasteride Dutch Bone Metastasis Study duvelisib DYNAMO study DYPD genotyping dysfagie dyslipidemia dyspnoe e-sigaretten E2F8 E3805-studie E3A06 study E3N E3N cohort E4 E5103 study E75 EA EAC early AYAs early breast cancer early cancer surveillance early diagnosis early metabolic response early mortality early noninvasive detection of response early onset CRC early onset female cancer survivors early phase ICI-trials early recurrence early stage breast cancer early thymic precursor acuut lymfoblastische leukemie early thymic precursor-like phenotype ALL early-life alcohol intake early-onset colorectal cancer early-onset familial breast cancer early-onset severe infections early-stage breast cancer early-stage endometrial cancer early-stage Hodgkin lymphoma early-stage lung cancer early-stage non-small cell lung cancer early-stage pediatric HL EBV EC ECD Echelon-1 studie ECHELON-1 study ECHELON-2 study ECHO-202 KEYNOTE-037 ECOG PS 2 ECOG-ACRIN 2511 study ECOG-ACRIN E1912 study ECOG-PS economic evaluation ECX) Edinburgh Pain Assessment and management Tool educational level één-maands mortaliteit eenarmige versus gerandomiseerde fase 2-studies eerdere kanker EF-14 EFVPTC EGFR EGFR mutated NSCLC EGFR T790M EGFR T790M-positive NSCLC in elderly patients EGFR-blokkade EGFR-mutant and MET-amplified NSCLC EGFR-mutant lung adenocarcinoma EGFR-mutant non-small cell lung cancer EGFR-mutant NSCLC EGFR-mutant NSCLC with liver metastases EGFR-mutated lung adenocarcinoma EGFR-mutated NSCLC EGFR-mutatie EGFR-mutaties EGFR-TKI EGFR-TKIs EGFR+ and ALK+ NSCLC EHCC eierstokkanker eiwitbiomarkers ELCC 2017 elderly cancer patients elderly patients electric power morcellation elevated vitamin B12 levels Eliasof ELOQUENT-3 study elotuzumab ELRP ELSA eltrombopag ELTS-score emactuzumab EMBRACA study EMBRACA-studie EMBRACE-studie embryonale hersentumoren EMD EMERGING-CTONG 1103 study emesis EMILIA emotionele uitputting EMT EMVI encorafenib ENCORE-601 study end-of-life care end-of-life zorg ENDEAVOR-studie endocriene behandeling endocriene effecten endocriene therapie endocrine deficiency endocrine diseases endocrine therapy endocrine therapy for breast cancer endocrine treatment endometrial ancer endometrial cancer endometrioïd endometriumcarcinoom endometrioïd epitheliaal ovariumcarcinoom endometrium-adenocarcinoom endometriumcarcinoom endometriumkanker EndoPredict endotheliaal ovariumcarcinoom ENDS energetic capacity ENESTfreedom enfortumab vedotin ENGOT-OV16 NOVA study ENGOT-OV16 NOVA trial enhanced recovery after surgery enhancer of zeste homolog 2 ENITEC consortium ENKTL ENLIVEN study entecavir enterovirus entrectinib Environmental Quality Index enzalutamide enzalutamide for castration-resistant prostate cancer ENZAMET study enzastaurine EOC EOPM EORTC EORTC 10995 EORTC 1325 Keynote-054 studie EORTC 18071 EORTC 22922 10925-studie EORTC 22952-26001 trial exploratory analysis EPA epacadostat EpCAM-positieve tumoren ependymoom EPHOS-B epi-drugs EPIC EPIC-analyse EPIC-NL EPICAP-studie epidural use epidurale metastasen epigenetic editing epigenetische stabiliteit epigenetische veranderingen epirubicin epitheliaal ovariumcarcinoom epithelial ovarian cancer epithelial ovarian cancer risk epithelial ovarian cancer survivors Epitopes-HPV02 ancillary study Epitopes-HPV02 study EPOC Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte EQoL-MDS ER status ER- en PR-testen ER-negatief mammacarcinoom ER-negatieve borstkanker ER-negatieve tumoren ER-positief HER2-negatief gevorderd mammacarcinoom ER-positief mammacarcinoom ER-positieve borstkanker ER-positive advanced breast cancer ER-positive breast cancer ER-positive HER2-negative breast cancer ER+ HER2- ER+ HER2- BC ERA 223 study ERAS ERBB2 HER2-positive metastatic breast cancer ERBB2 mutations in solid tumors ERBB2 plasma copy number Erdheim-Chester disease erfelijke borst- en eierstokkanker erfelijke syndromen erfelijkheid eribulin eribuline ErkentNIS erlotinib ersatzdroge Erβ1 Erβ2 ES-NSCLC ES-SCLC ESCC ESCC detection by microRNA profiling ESD ESGC ESHAP ESMO esomeprazole esophageal adenocarcinoma esophageal and GEJ adenocarcinoma esophageal cancer esophagogastric cancer surgery ESR1-amplificatie estetrol esthesioneuroblastoom esthetische uitkomst estrogen monotherapy ET etirinotecan pegol etnische diversiteit ETP-ALL LBL ETS EU-regelgeving EURECCA Euro-E.W.I.N.G.99 Euro-Ski EURO-SKI studie EUROCARE-5 European cancer mortality European Code against Cancer Europese kankermortaliteit EURTAC EUTOS EV-201 study EV-assay EVAN study everolimus everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer everolimus plus pazopanib everyday clinical practice evofosfamide Ewing sarcoma Ewing sarcoom Ewing-2008 ex vivo IFNγ production exceptional responder EXCITE-studie exemestaan exemestaan plus everolimus exemstaan exercise intervention in cancer patients exercise versus usual care exhaled breath tests exome sequencing-based screening exosomen expansie van fase 1-studie PCD4989g Exploratieve analyse MARQUEE-studie exposoom expressie stromagenen in CRC EXPRESSION III-studie extended follow-up of PALOMA-2 study EXteNET ExteNET-studie extensive stage extensive-stage small-cell lung cancer external beam radiation therapy extracapsular extension in sentinel node extrahepatisch cholangiocarcinoom extranodal natural killer T-cell lymphoma extranodale extensie extrapleural pneumonectomy extrauterine disease EZH2 FACE facial nerve function facial-aging app facility volume factors predicting invasive breast cancer recurrence FALCON false positive FIT familair mammacarcinoom familiaal colorectaalcarcinoom familiaal risico familiaire adenomateuze polyposis familiaire adenomateuze popyposis familial platelet disorder familiale adenomateuze polyposis familiegeschiedenis familiegeschiedenis prostaatkanker family history family history of breast cancer family history of cancer FaMRIsc study fase 2-studie BOLERO-4 fase 2-studie BOLERO-6 fase 2-studie KEYNOTE-224 Fase 2-studie SWOG S0801 fase 3- studie DREAM fase 3-studie AURA3 fase 3-studie BrighTNess fase 3-studie COLUMBUS Fase 3-studie CRITICS fase 3-studie ETNA fase 3-studie FATA-GIM3 fase 3-studie GEC-ESTRO Fase 3-studie KEYNOTE-045 fase 3-studie METEOR Fase 3-studie MONALEESA-3 fase 3-studie MONALEESA-7 fase 3-studie NETTER-1 Fase 3-studie PERSEPHONE fase 3-studie PRODRIGE 9 Fase 3-studie SAKK 75 08 Fase 3-studie SWOG S9921 fase 3-studie TROG 05.01 fase 3-studies fatal ICI-associated toxic effects fatalisme fatigue fatigue in cancer patients FCR FCT FDA-approved novel oncology drugs FDG-PET FDG-PET CT FDG-PET scanning febriele neutropenie fecale immunochemische test female breast cancer risk fentanyl fentanyl sublinguale spray fenylketonurie hyperfenylalaninemie fermented dairy foods fertiliteitspreservatie fertility drugs fertility treatment FGFRs FH02 study FHWT FIA FIGHTDIGO-studie fijne motoriek fijnstof FIL-HD0801 study Finale analyse FIRST-studie finale analyse van GOG 240-studie finale overlevingsresultaten van KEYNOTE-006 financiële toxiciteit finasteride fine-needle biopsy FinXX-studie FIR-studie FIRE-3 firefighters FIRES first line therapy first-degree relatives of pancreas cancer patients first-line carboplatin versus cisplatin first-line CLL treatment first-line mFOLFOX6 plus bevacizumab versus cetuximab first-line pembrolizumab first-line pembrolizumab for advanced NSCLC with low PD-L1 expression FIRSTANA-studie FIT FIT cohort FIT screening FIT-detection of advanced colorectal neoplasia FIT-screening fitheid fitness five miRNA-model five-miRNA based classifier five-year PROs five-year survival outcomes fixed duration of venetoclax-rituximab FKBPL FL FLAURA study FLAURA-studie flavonoïden flexibele sigmoïdoscopie flexibele-sigmoïdoscopie FLOT4 study FLOT4-studie FLT3-internal tandem duplication mutated AML FLT3-ITD positive AML fludarabine FLUOGLIO-studie fluoropyrimidine therapy fluoropyrimidines fluoroscopie fluorouracil-leucovorin FLYER study FNMTC focal adhesion kinase FOCUS-cohort Fol-BRITe study FOLFIRI FOLFIRINOX FOLFOX FOLFOX4 FOLFOXIRI foliumzuur FOLL05-studie folliculair lymfoom follicular lymphoma Follow-up analyse van CheckMate 067-studie follow-up analyse van JFMC34-0601 follow-up van overlevers formaldehyde FOrMAT-studie fosaprepitant fosaprepitant meglumine fotofarmacologie FOXA1-expressie FOXA2 FOXC1 FPD AML fractionated stereotactic radiotherapy fracturen fractuurrisico fragiele ouderen fragiliteit frequent cystoscopy FRESCO study fresolimumab front-line ibrutinib for CLL patient populations not included in RESONATE-2 frontline targeted therapy plus low-intensity chemotherapy frontline therapy for AML in elderly patients fruit fruit and vegetable consumption fruquintinib FSRT FSS versus RS FTD versus HD-MA FTL3-mutatie fulvestrant fulvestrant versus AIs FUS-ERG and RUNX1-CBFA2T3 fusion gene Fusobacterium nucleatum fysieke activiteit G-CSF support G-CSFs G84E gain-of-function mutatie gait speed galactography galblaascarcinoom GALEN study galeterone gallium-68 labelled PSMA-11 PET GALLIUM-studie galunisertib galwegcarcinoom gamma knife radiosurgery ganglioside-monosialic acid ganitumab GARD gastric adenocarcinoma gastric cancer gastric or gastro-esophageal junction cancer gastric or gastroesophageal junction adenocarcinoma gastric or gastroesophageal junction cancer gastric or GEJ adenocarcinoma gastro-intestinale mucositis gastro-intestinale stromale tumoren gastro-oesofagaal adenomcarcinoom gastroesophageal adenocarcinoma gastrointestinal stromal tumor gastrointestinal stromal tumors gastroïntestinale kanker gastroïntestinale stromale tumoren Gattelli GAUDI GBC GBCA GBM GBM in elderly patients GBS GBSM GBV-C GC GC1008 GCA GCC GCT GCTB GCTs GD GDP GEC GeDDiS-studie gedifferentieerd schildkliercarcinoom gedissemineerde tumorcellen gefitinib gefitinib continuation after progression GEICAM 2010-04 study gelokaliseerd prostaatcarcinoom GEM gemcitabine gemcitabine plus cisplatin induction chemotherapy gemcitabineresistentie gemetastaseerd mammacarcinoom gemetastaseerd melanoom gemetastaseerde borstkanker gemetastaseerde borstkanker; trastuzumab gemetastaseerde colorectaalkanker gemtuzumab ozogamicin gemtuzumab ozogamicine gender differences geneesmiddelinteracties Generations Study genetic prognostic and predictive factors genetic testing genexpressie genito-urinaire maligniteiten genmethylering genome sequencing genome-wide association study genome-wide diet-gene interaction genomic biomarkers predicting anti-PD-(L)1 response genomic correlates of progression or response genomic profiling genotyping lung adenocarcinoma genvarianten GEP-NETs GeparNuevo study GeparQuattro-studie GeparSepto GeparSepto long-term outcomes GeparSixto trial gepegyleerd liposomaal doxorubicine gerandomiseerde fase 2-studie PrE0102 GERD treatment Gerecke geriatirc patients Geriatric Prognostic Indicator germ cell tumors germline BARD1 gene variants germline BRCA-mutated metastatic pancreatic cancer germline mutaties germline mutations geserreerde poliepen geslachtshormonen gestation and birthweight of offspring gestationele trofoblasttumor gevorderd cervixcarcinoom gevorderd maag-adenocarcinoom gevorderd melanoom gevorderd niercelcarcinoom gevorderde borstkanker gevorderde maagkanker geweichtsverlies gezondheidsutiliteitsindex gFOBT GFR GFR; niercelcarcinoom; urotheelcarcinoom GHSG HD13-15 trials gilteritinib GIST GLARIUS-studie glasdegib Gleason score 9-10 prostate cancer glembatumumab vedotin glioblastoma glioblastoma multiforme glioblastoma with methylated MGMT promoter glioblastoom glioma glioma risk gliomas gliomen glioom glitazonen Global Burden of Cancer glottic squamous cell carcinoma glucocorticoid treatment glucose lowering drugs GLUT- GLUT-14 glutathion-S-transferase P1 glycaan-gerelateerde genen glypicaan-1 GM-CSF GNCC GnHRa GnRH-agonist GO GOG-0213 studie GOG-0218 final OS-analysis GOG-0218 studie GOG-0277 Golestan Cohort Study gonadotropine Google Translate GORTEC 2007-01 studie gosereline GOYA-studie graft failure graft versus host disease graft-versus-host disease graft-versus-host disease prophylaxis GRASPA GRECCAR 2-studie grijpkrachtverlies grip strength groeicurves naevi groeisnelheid groenten groentenconsumptie grootcellig granulair lymfocytaire leukemie grootcellig neuro-endocrien longcarcinoom grootte van lymfekliermetastasen grote-korrel lymfocyten leukemie growth hormone deficiency growth rate of untreated hemangioblastomas GSK2857916 GU-toxiciteit guadecitabine guanylaatcyclase GVAX pancreas GVHD GWAS gynecological brain metastases gynecologische maligniteiten haarverlies hafnium oxide nanoparticle HAI HAIC hairy cell leukemia hairy-cell leukemie hallmarks of cancer HALO 202-studie Ham-Wasserman lecture Hamilton Fairley Award hand-voet huidreacties hand-voet syndroom hand-voetsyndroom HannaH study final analysis haplo-HSCT haplo-HSCT versus chemotherapy haplo-identieke HSCT haplo-SCT haploidentical; sibling; matched unrelated donor HART hartfalen hartfalen na auto-HCT HBOC HBV-related HCC HBV-related HCC risk HBV-vaccinatie HC hcc HCC overall survival HCC with portal vein tumor thrombus HCT HCV HD IL-2 HD12 study HD18-studie HD9 study HDAC inhibition HDR-brachytherapie head and neck cancer head and neck cancer risk after hematologic cancer head and neck procedures head and neck squamous cell carcinoma head en neck cancer health maintenance practices Health Professionals Follow-up Study health-related quality of life healthy immigrant effect healthy older adults heavy smokers hedgehog-signaalroute heldercellig niercelcarcinoom heldercellig ovariumcarcinoom Helicobacter pylori HELIOS study hematologic malignancies in older patients hematologic malignant neoplasms hematologische maligniteiten hematopoietic cell transplantation hematopoietic stem cell transplantation hematopoïetische celtransplantatie hepatitis B virus infection hepatitis B-virus hepatitis C hepatocallular carcinoma hepatocellulair carcinoom hepatocellular carcinoma hepatocellular carcinoma with portal vein invasion hepatospleen T-cel lymfoom hepatotoxiciteit hepatotoxicity HER2 HER2 amplification HER2 exon 20 insertions HER2 pro-oncogene signalering HER2-amplified mCRC HER2-expressie HER2-expressing cancers HER2-gedreven NSCLC HER2-mutant lung cancer HER2-negatief mammacarcinoom HER2-negatieve borstkanker HER2-negatieve MBC HER2-negative HER2-negative metastatic breast cancer HER2-overexpressing breast cancer HER2-positief mammacarcinoom HER2-positief metastatisch mammacarcinoom HER2-positieve borstkanker HER2-positieve vroege borstkanker HER2-positive breast cancer HER2-positive breast cancer with brain metastases HER2-positive early breast cancer HER2-positive localized breast cancer HER2-positive MBC HER2-positive metastatic breast cancer HER2-positive salivary duct carcinoma HER2-scoringsysteem HER2-screening HER2-targeted CAR T cell therapy HER2-targeted therapies HER2-targeted therapy HER2+ BC HER2+ breast cancer HER3-mutant mammacarcinoom HERA HERBY-studie herceptin herceptin-biosimilar herceptine Heritage heropname herpes zoster after autologous stem cell tranplantation hersenmetastasen hersenmetastasen mammacarcinoom hersenmetastasering hersenmicrobloedingen hersentumoren Heterocephalus glaber heterogeneity between SEER counties HF-WBI HFSRT HGG HGS OC HGSOC HIFU high risk locally advanced rectal cancer high risk melanoma high sensitivity C reactive protein high-dose-rate brachytherapy high-grade glioma high-grade prostate cancer high-intensity focused ultrasound high-intermediate and high risk early stage EC high-mobility group box 1 High-molecular-mass hyaluronan high-risk ALL in children high-risk breast cancer high-risk cancer surgery high-risk endometrial cancer high-risk luminal breast cancer high-risk melanoma high-risk neuroblastoma high-risk prostate cancer high-risk smoldering multiple myeloma high-risk uveal melanoma HIIT HiLo trial HIPEC HIPEC + CS histological biomarkers histologische regressie histopathologic features HIV HIV AIDS HIV infection HIV-associated Kaposi sarcoma HIV-infection HL HL-behandeling HLA antigen mismatch hMPV HMR 2.0 HNC HNCs HNSCC HNSCC surgery Hodgkin lymfoom Hodgkin lymphoma Hodgkin's lymfoom Hodgkin’s lymphoma hofd-hals Merkel celcarcinoom hoge dosering chemotherapie Hokusai VTE-Cancer studie homeobox B13 homocysteïne homologous recombination deficiency hoofd hals squameus celcarcinoom hoofd halscarcinoom hoofd halskanker hoofd-hals melanoom hoofd-hals squameus celcarcinoom hoofd-halscarcinoom hoofd-halskanker hoofdhuidkoeling hoog-risico B-ALL hoog-risico cervixcarcinoom hoog-risico CML hoog-risico melanoom hooggradig sereus ovariumcarcinoom horizontale transfer hormonal therapy hormonal therapy resistance hormoonreceptor positieve borstkanker hormoontherapie hospital volume hospitalisatie hospitalization hot flashes HOVON 105 ALLG NHL 24 How Long studie HP SCC HPC-SFT HPD HPTC HPV HPV ctDNA HPV DNA in penile cancer and intraepithelial neoplasia HPV DNA persistence HPV status HPV types 16 18 in cervical precancers HPV vaccination HPV-16 18 vaccin HPV-associated epithelial cancers HPV-FOCAL trial HPV-infectie HPV-negative HNSCC HPV-orofarynxcarcinoom HPV-positive oropharyngeal cancer HPV-typen HPV-vaccinatie HPV16-related cancerISA101 HR-deficiëntie HR-NB HR-NL81 SIOPEN HR-positief mammacarcinoom HR-positief metastatisch mammacarcinoom HR-positive advanced postmenopausal breast cancer HR-positive breast cancer HR-positive early-stage breast cancer HR-positive HER2-negative advanced breast cancer HR-positive metastatic breast cancer HR-status HR+ HER2- vroeg-stadium mammacarcinoom HR+ HER2+ breast cancer HR+ MBC HRBOC HRQoL HRQOL in prostate cancer HRT HRT versus CRT HSC HSCT HSCT-bijwerkingen Hsp70 HT hTERT-DCs hu3F8 huidkanker huidkankerscreening huidmaligniteit huidneoplasmen huisartsenzorg humaan papillomavirus human equilibrative nucleoside transporter 1 human readers versus machine-learning algorithms hybrid minimally invasive esophagectomy hyperbaric oxygen therapy hypercalcaemia of malignancy hypercalcemie hyperemesis gravidarum hyperprogressive disease hyperproliferatie van stamcellen hypertensie hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery hyperthermische intraperitoneale chemoperfusie hypervascular intracranial tumors hypodiploid ALL in children hypofarynxcarcinoom hypofractionated IMRT hypofractionated postmastectomy radiotherapy hypofractionated versus conventionally fractionated whole-breast irradiation hyponatremie HYPOR HYPRO i-ALCL iAMP21 IARC IBC IBCSG 23-01 trial IBD IBIS II IBIS-I IBM Watson IBR ibrutinib ibrutinib discontinuation ibrutinib plus fludarabine ibrutinib plus palbociclib ibrutinib plus venetoclax ibrutinib versus ofatumamab ibuprofen ICC ICI treatment ICIs ICIs for NSCLC ICIs plus chemotherapy ICLL07 FILO study ICON6-studie ICON8-studie ICPi ICU-opname iddEPC-studie IDEA-collaboration idelalisib IDH mutation IDH1-expressie idiopathische membraneuze nefropathie idiopatische MCD Idylla IELSG-19 studie IELSG32-studie IES IFD IFG IFM 2009 IFN-onderhoudsbehandeling IFRT IGBT IGF-1 IGF-1R expressie IGF2-AS IgM MGUS IGT IHCA IHCC IHGV mutational status IIIA-N2 NSCLC ijzersuppletie IKFZ1-deletie IKFZ1-deletion IKZF1-deletie IL-6 IL-8 ILC illness perception and outcomes in cancer iLLUMINATE study image-guided intensity modulated radiation therapy Imaging imaging surveillance IMAJEM-studie imatinib imetelstat IMiDs imiquimod immediate vs deferred cytoreductive nephrectomy IMmotion 151-studie IMmotion151 trial immune checkpoint blockade immune checkpoint inhibition Immune Checkpoint Inhibitor immune checkpoint inhibitor for NSCLC immune checkpoint inhibitors immune markers of nivolumab response immune-mediated diarrhea and colitis immune-related adverse events immunocheckpoint blockade immunochemottherapy immunoglobuline lichte-keten amyloïdose immunophenotyping of TILs and PBLs immunosuppressive therapy for management of MDS immunotherapy immunotherapy-related pruritus immutherapy immuuncheckpointremmers immuunrespons immuunsuppressie immuuntherapie IMPAC IMPACT impact of adjuvant regimes impact of age impact of antibiotics impact of attending surgeon impact of centralization within hospital systems impact of conditioning intensity impact of detailed family history impact of diet impact of disease stage impact of ER status on survival impact of follow-up time impact of HIV infection impact of hormone receptor status impact of pre-existing CVD on mortality impact of pregnancy on genomic landscape impact of primary tumor surgery impact of prior therapy impact on outcomes impact on sexual function impact on survival IMPACT-studie IMPACT2 IMpassion130 study IMpassion130 trial IMPATTO study IMPORT LOW study IMpower130 trial IMpower133 Study IMpower150 study IMpower150-studie IMPRESS-studie IMPROVE study IMPT IMRT IMT IMvigor211-studie in situ mammacarcinoom incidence incidence of pneumonitis incidence trends incident cancer risk incidental pulmonary embolism in cancer patients incidentally found pediatric brain tumors incidentie incidentie mammacarcinoom USA increased α-fetoprotein increasing dose intensity of chemotherapy INDAR independence indeterminate pulmonary nodules individual oncogenic HPV types individual patient-level analysis indolent lymfoom indolent mammacarcinoom indoor tanning inductie-chemoradiatie inductiechemotherapie induction chemotherapy infants infectie infigratinib inflammatie inflammation cascade Inflammatoir mammacarcinoom inflammatoire voeding inflammatory bowel disease inflammatory markers influenza vaccination influenzavaccinatie infradiaphragmatic disease inhaled corticosteroids INHANCE-consortium iNHL iniparib INITIATE study iNNOVATE iNNOVATE-studie InnovaTV 201 study INO-VATE studie inotuzumab ozogamicin INSIGHT-studie inspanning Institute of Cancer Research insulin resistance insulin-like growth factor insulinemie insulineresistentie intake of whole grains and dietary fiber INTEGRATE INTENS-studie intense androgen deprivation before prostatectomy intensieve chemotherapie inter- and intra-laboratory variation Intergroup Exemestane Study intermediate recurrence score intermediate- or high-risk GIST intermediate-risk AML intermittent nivolumab intermittent versus continous PEG-asparaginase intermitterende claudicatie International Breast Cancer Intervention Study I International Childhood Cancer Cohort Consortium International Male BC Program international variation in radiation dose internet-steunprogramma's interval cancers intervalcarcinomen intervals to diagnosis intra-tumor heterogeniteit intracraniaal ependymoom intraductale papillaire mucineuze neoplasie intraductale papillaire mucineuze neoplasmen intrahepatic cholangiocarcinoma intrahepatisch cholangiocarcinoom intraoperative peritoneal lavage intraperitoneale chemotherapie intratumorale genetische heterogeniteit intratumorale genoomdiversiteit intrauterine devices intravitale microscopie intrinsic subtype analysis of BOLERO-2 intrinsiek subtype intrinsieke subtypes intrinsieke subtypes mammacarcinoom invasieve borstkanker invloed behandelcentrum op overleving ioniserende straling iontoforese IORT IOTA5 study ipatasertib IPH4102 ipilimumab ipilimumab plus nivolumab ipilimumab versus pembrolizumab IPMN ipsilateral breast event IPTT irAEs IRd IRE irinotecan irinotecan dose IRIS isatuximab iscocitraatdehydrogenase isocitraatdehydrogenaseremmer isolated breast pain Italiaanse cultuur ITOMIC-001 studie IV versus IP chemotherapy plus bevacizumab IVF IWDD ixazomib ixazomib maintenance ixazomib of placebo toegevoegd aan lenalidomide-dexamethason J-ALEX studie JACC-studie JACCRO GC-07 study JACOB study JAKARTA-2 studie jandus Janus Cohort JAVELIN Lung 200 study JAVELIN Merkel 200-studie deel B JAVELIN ovarian cancer cohort JAVELIN Renal 100-studie JAVELIN Renal 101 study JAVELIN Solid Tumor studie JAVELIN Solid Tumor trial JAVELIN Solid Tumor trial mesothelioma cohort JCOG0203 trial JCOG0504-studie JCOG0910-studie JCOG1001-studie JFMC37-0801 study JGO job-exposure matrices jodium-131 JPHC nested case-control study JULIET-studie kanker kanker bij kinderen kanker-immunotherapie kankerchirurgie kankerincidentie kankermortaliteit kankermortaliteit 2015 kankerpijn kankerrisico kankerrrisico kankersterfte kankersubtypes KATHERINE study katheter KC KDD keratinocytcarcinoom keratinocyte carcinoma Keratinocyte Carcinoma Chemoprevention Trial kerncentrales ketotifen KEYNOTE-001 KEYNOTE-001 (secundaire analyse) KEYNOTE-001 study KEYNOTE-010 KEYNOTE-012 KEYNOTE-017 study KEYNOTE-020 KEYNOTE-021 KEYNOTE-021 study KEYNOTE-024 KEYNOTE-028 KEYNOTE-028 and -158 pooled analysis KEYNOTE-028 studie KEYNOTE-028 study KEYNOTE-029 KEYNOTE-029 studie KEYNOTE-040 study KEYNOTE-042 study KEYNOTE-045 KEYNOTE-052 studie KEYNOTE-055 KEYNOTE-059 studie KEYNOTE-061 studie KEYNOTE-086 cohort A KEYNOTE-086 cohort B KEYNOTE-087 KEYNOTE-100 study KEYNOTE-158 study KEYNOTE-164 studie cohort B KEYNOTE-180 study KEYNOTE-181 KEYNOTE-181 study KEYNOTE-189 studie KEYNOTE-240 study KEYNOTE-407 KEYNOTE-426 study KEYNOTE-427 study cohort B Khorana-score Ki-67 Ki67 kidney cancer kidney stones and risk of RCC and UTUC kidney transplant recipients kiemceltumor kiemceltumoren kinaseremmers kinderkanker KIT klachten aromataseremmers KLASS-01 studie klassiek Hodgkin lymfoom klein lymfocytair lymfoom kleincellig longcarcinoom kleincellig prostaatcarcinoom kleincellige longkanker kliernegatief mammacarcinoom klierpositief mammacarcinoom koffie koffieconsumptie kosten behandeling HER2-positief MBC kosten van gezondheidszorg kosteneffectiviteit hematologische middelen kosteneffectiviteit screening KP-BSI KRAS KRAS mutation KRAS-mutatie KRAS-mutaties KRISTINE study KRISTINE-studie KS KSHV-transmissie kwaliteit van leven L-COSY LA-ESCC LA-HNSCC LA-NSCLC laag-moleculairgewicht heparine laag-vet voeding laaggradig glioom laaggradig niet-spierinvasief urotheelcarcinoom laaggradig sereus ovarium- of peritoneaal carcinoom laat recidief coloncarcinoom LABC LACE-Bio studies LACE-Bio-II study LACE-studie LAcSCC LADG LAFA-studie LAHNC LAM LAM-SA 2007 study Lancet Haematology Lange-termijn analyse van SBG 2004-1 studie lange-termijn follow-up van KEYNOTE-001 lange-termijn uitkomsten GeparQuinto langerhanscel histiocytose LAP07 laparoscopic versus open distal gastrectomy laparoscopic versus open surgery laparoscopie laparoscopische chirurgie laparoscopische hysterectomie laparoscopische ingreep laparoscopische resectie lapatinib LAPC LARC large brain metastases laryngectomy laryngectomy outcomes larynxcarcinoom larynxkanker larynxpreservatie Lasker Award late lower cranial neuropathy late mortaliteit late recurrence late recurrence after liver resection Lateral Node Study LATITUDE study LATITUDE-studie LAVC LCH LCL161 LCNEC LCS-6 KRAS LE LEA-studie LEBS leefstijl leefstijl-geassocieerde maligniteit leefstijlfactoren leefstijlinterventies leeftijd left lung cancer leighl leiomyomatose leiomyosarcoom lenalidomide lenalidomide maintenance versus observation lenalidomide plus rituximab lenvatinib lenvatinib plus pembrolizumab leptomeningeal disease in metastatic melanoma patients leptomeningeal disease recurrence leptomeningeal metastases from NSCLC leptomeningeale ziekte letrozol letrozole letrozole for early breast cancer leucine-rich repeating G-protein-coupled receptor 5 leukemia leukemia cutis leukemie leukemie in kinderen leukocyt-telomeerlengte leukocytenattractie leukocytosis leumie levensverwachting levercarcinoom levercelcarcinoom levercelkanker leverfunctie leverkanker levermetastasen LFS LGG LGG before one year of age LGSC Li-Fraumeni syndrome Li-Fraumeni syndroom lichaamsgewicht lichaamslengte lichaamsomvang lichaamsvet lichaamsvetgehalte lichte keten-geassocieerd Fanconi syndroom lidocaïne lieu lifestyle lifestyle intervention ligating veins first versus arteries first LINC00472 linsitinib lip-SCC LIPI liposarcoom lipoxygenases liquid biopsy liquide biopten Listeria expressing mesothelin LITT liver cancer liver cancer mortality liver cancer risk liver metastatic breast cancer LLPCa LM LMB-2 LMR LNC-PATH score lncRNAs lobectomie lobulair carcinoom in situ lobulair mammacarcinoom local consolidative therapy local recurrence local therapy localized pancreatic cancer localized prostate cancer localized renal cell carcinoma localizing recurrent prostate cancer locally advanced cervical cancer locally advanced gastric cancer locally advanced laryngeal cancer locally advanced lung cancer locally advanced non-small cell lung cancer locally advanced NSCLC locally advanced pancreatic cander locally advanced prostate cancer locally recurrent or metastatic HER2-positive breast cancer locatie locatie van overlijden locoregionaal recidief locoregional recurrence Locoregional recurrent rhabdomyosarcome locoregionale behandeling LOH lokaaal-gevorderd rectumcarcinoom lokaal gevorderd prostaatcarcinoom lokaal gevorderd rectumcarcinoom lokaal recidiverend mammacarcinoom lokaal-gevorderd hoofd-halscarcinoom lokaal-gevorderd metastatisch mammacarcinoom lokaal-gevorderd rectumcarcinoom lomustine lomustine plus temozolomide long-term CRC risk long-term disease-free breast cancer survivors long-term follow-up long-term follow-up BIG 1-98 trial long-term follow-up KEYNOTE-012 long-term health outcomes long-term outcomes long-term results OlympiAD study long-term risk of endocrine and metabolic diseases long-term risk of hospitalization long-term somatic disease risk long-term survival long-term survivors NHL long-term survivos of childhood cancer long-term thyroid cancer risk longadenocarcinoom longcarcinoom longer intervals after negative low-dose CT result longfunctie longkanker longkanker-screening longkankerchirurgie longkankerscreening longmetastasen lorlatinib loss of life expectancy LOTUS-studie low cT3 4 rectal cancer low dose radioiodine ablation low grade and anaplastic glioma low grade glioma low-dose aspirin low-grade glioma in children low-intensity chemotherapy low-risk prostate cancer LP LPHL LPPG LPS LR-HL LRBC LRC LRR LS LS-SCLC LTL LTLD LUAD LUME-Meso studie luminal B LUNA-studie lung adenocarcinoma lung and colorectal cancer lung cancer lung cancer mortality lung cancer risk lung cancer screening lung cancer screening efficacy lung cancer surgery lung cancer survivors lung nodule progression to cancer LUNGSTAR LuPSMA LuPSMA-studie lurbinectedin lutathera LUX-Lung3; LUX-Lung6 LV-V5 LY3039478 lycopeen LYM-3002 LYM-3002 study lymfadenectomie lymfekliermetastasen lymfeklierpositiviteit lymfoblastisch non-Hodgkin lymfoom lymfocyten lymfocyteninfiltratie lymfoedeem lymfoïde neoplasie lymfoom lymph node burden lymph node macrometastases lymph node ratio lymphadenectomy lymphatic versus hematogneous dissemination lymphedema lymphoma Lymphome Malin de Burkitt chemotherapy lymphopenia lymphoscintigraphy Lynch syndrome Lynch syndrome associated cancers lynch syndroom Lynch syndrooom LYRA study M-trap MA.17R MA.17R-studie MA.27 maag maag-slokdarmovergangkanker maag-slokdarmadenocarcinoom maagadenocarcinoom maagcarcinoom maagkanker MaBC MabEase-studie MABLE-studie MACBETH-studie MACRO2 TTD study Magee Equation 3 MAGIC-studie magnesiuminname MAIA study main-duct intraductal papillary mucinous neoplasms maintenance therapy maintenance treatment MAJA study MAJA-studie major head and neck surgery MALDI-MS male breast cancer male pattern baldness male sex disease-specific mortality male-pattern baldness malignant melanoma malignant mesothelioma malignant pleural disease malignant pleural effusion malignant pleural mesothelioma maligne ascites maligne glioom maligne pleura mesothelioom maligne pleuraal mesothelioom Malmö Breast Tomosynthesis Screening Trial Malmö Diet and Cancer Study MALT lymfoom MALT-IPI MALT-lymfoom mamacarcinoom mammacarcinoom mammacarcinoom in mannen mammacarcinoom mannen mammacarcinoom; SABCS 2015 mammacarcinoom. lichaamsgewicht mammacarcinoomscreening mammacarcinooom mammacarcionoom mammacarcioon MammaPrint MammaPrint-assay mammografie mammografiescreening mammographic surveillance in young women mammography mammography breast cancer screening in high-risk males mammography screening MAN mannen Mannuci mantelcellymfoom mantle cell lymphoma MAPS IFCT-GFPC-0701 study MAPS2-studie MARCH marginaal zone lymfoom marginal zone lymphoma MARIE study MARIE-cohort marihuana marijuana use marizomib marker borstkanker MARQUEE study masitinib MasSpec Pen mastectomie mastectomy versus lumpectomy plus RT maternal breast cancer risk MATISSE-studie matrix metalloproteïnase-8 MAVORIC study MAVORIC-studie MaxRP MaxRT MBC MBI MBL MBMs MCC MCL MCL in older patients mCRC mCRPC mCSPC MD MDS MDS or AML MDTB mebendazol medical decision-making capacity medische marihuana mediterrane voeding MEDOCC medullair schildkliercarcinoom medullair thyroïdcarcinoom medulloblastoma medulloblastoom meeroken MEI MEK- plus AKT-remming MEK-remmers MEK-remming melanoma melanoma brain metastases melanoma in adolescents and young adults melanoma in children and adolescents melanoma of unknown primary melanoom melanoom-geassocieerde leucoderma melanoom-mortaliteit melanoomrisico melatonine melfalan melkconsumptie MEN1 meningioma meningioma risk factors meningioom menopauzale hormoontherapie mental health disorders mentale stoornis Merkel celcarcinoom Merkelcelcarcinoom MESCC mesothelin-targeted CAR T cells mesothelioom mestcel-neoplasmata MET exon 14 altered lung cancer MET-amplificatie meta-analysis meta-analysis of studies of immunotherapy for NSCLC metabole gezondheid metabolic dysregulation metabolic health metabool syndroom metastase metastasectomie metastasering metastasevrije overleving metastasis-free interval metastatic breast cancer metastatic breast cancer in geriatric patients metastatic cardiophrenic lymph nodes metastatic castration-resistant prostate cancer metastatic castration-sensitive prostate cancer metastatic colorectal cancer metastatic colorectal cancer cetuximab plus FOLFOX-4 metastatic colorectal cancer in older vulnerable patients metastatic esophageal cancer metastatic esophagogastric adenocarcinoma metastatic esophagogastric cancer metastatic gastric cancer metastatic gastric or junctional adenocarcinoma metastatic HER2-positive breast cancer metastatic hormone-sensitive prostate cancer metastatic melanoma metastatic nasopharyngeal carcinoma metastatic non-small cell lung cancer metastatic nonsquamous NSCLC metastatic osteosarcoma metastatic pancreatic adenocarcinoma metastatic pancreatic cancer metastatic pancreatic ductal adenocarcinoma metastatic prostate cancer metastatic renal cell carcinoma metastatic triple-negative breast cancer metastatisch castratieresistent prostaatcarcinoom metastatisch cervixcarcinoom metastatisch colorectaalcarcinoom metastatisch colorectaalkanker metastatisch colorrectaalcarcinoom metastatisch heldercellig niercelcarcinoom metastatisch maagcarcinoom metastatisch mammacarcinoom metastatisch melanoom metastatisch niercelcarcinoom metastatisch niet-castratieresistent prostaatcarcinoom metastatisch pancreas ductaal adenocarcinoom metastatisch pancreascarcinoom metastatisch PDAC metastatisch potentieel metastatisch prostaatcarcinoom metastatisch squameus celcarcinoom van hoofd en hals metastatische borstkanker metastatische botziekte metastatische castratieresistente prostaatkanker metastatische colorectaalkanker metastatische niet-kleincellige longkanker metastatische prostaatkanker metastatische triple-negative borstkanker METEOR METEOR-studie metformin metformine methionine methotrexate neurotoxicity metronome chemotherapie MF mFOLFOX6 MGPT MGUS MHD MHSs MHT MIBC MIC-1 microductectomy microRNA-203 microRNA-371a-3p test microRNA-classifier microRNAs microsatelliet-instabiele kanker microsatellite instability microsatellite instability-high mCRC middel-heupomtrekverhouding middelomtrek middelomvang midgut NETs migraine migratie naar hersenparenchym MILD trial MILES-3 MILES-4 million women study MILS MINDACT mindfulness mindfulness-based cognitive therapy minimal residual disease minimally invasive robotic surgery minimally invasive versus open surgery mipsagargin MIPSS70 miR-126 miR-190b miR-34 miR-345 miR-506 miRNA miRNAs MIRO-studie Mitchell MITCI-studie MITO-8 studie MITO-9 study mitomycin C mitosesnelheid mitotische activiteitsindex mitoxantrone MK-2206 MK-3475 MLBO MM MM-302 MMR MMR-deficiency MMR-deficiëntie MMSE mNPC mNSCLC MNTX mode of detection mode of progression moderately hypofractionated helical IMRT moderately hypofractionated IMRT modern chemotherapy mogamulizumab moleculaire subtypen moleculaire tumormarkers molecular classification molecular markers of prognosis molecular markers of recurrence molecular subtypes molecular subtypes of breast cancer Molina MONALEESA-2 studie MONALEESA-7 studie MONALEESA-7 trial MONARCH 1 MONARCH 1-studie MONARCH 2 study MONARCH 2-studie MONARCH 3-studie mondholte squameus celcarcinoom mondholtecarcinoom mondhygiëne mondkanker monoklonale B-cel lymfocytose Moore-criteria morcellatie mortaliteit mortaliteit colorectaalcarcinoom mortaliteit na kankerdiagnose mortality mortality after breast cancer mortality as function of age mortality from unrelated causes mortality trends mortalteit MOSAIC MOSAIC trial post hoc analysis moxetumomab pasudotox mPCa mPDAC MplBC MPM MPN mRCC MRD-status MRD-stratified treatment MRI MRI background parenchymal enhancement MRI staging of breast camcer MRI-FIRST study MRI-screening MRI-screening mammacarcinoom MS2010 study MSC MSE MSG-carcinomen MSI-CRC MSLCs MSLT-II studie MT-GCT MTC mtDNA MTH1-remmers mTNBC mTOR-remmer mTOR-remmers mUC MUC16 mutations mucosaal melanoom mucosalaesies mucositis mucositispijn mulitpel myeloom Müllerian carcinoom multi-gen panel testing HBOC multidisciplinary salvage treatment multidrugresistentie Multiethnic Cohort multikinase inhibitors multipel myeloom multipel myeloom. KTd multipele endocriene neoplasie multiple myeloma multiple myeloma refractory to CD38 MoABs MULTOMAB study MURANO study MURANO-studie muscle-invasive bladder cancer musculoskeletal burden mutatiescreening mutatievolgorde mutation burden mutation clearance mutation profiling mutation status and prognosis mutations in cancer-associated genes mutations in cancer-related genes mutp53 proteins muziektherapie MVAC MVPA MYC Myc-remming MYCN mycosis fungoides myelodysplasie myelodysplastic syndrome myelodysplastisch syndroom myelodysplastisch syndroom myeloproliferatieve neoplasmen myelodysplastische syndromen myelofibrose myelofibrosis myeloid malignancies myeloïde neoplasie myeloma Myeloma X trial myeloom myeloproliferatieve neoplasmen MYL-14010 myocarditis myomectomie MyPathway study MyPathway-studie myxoid liposarcoma MZL n-3 fatty acids N-cadherine N1087-studie N3 stage IIIB NSCLC in elderly patients NA-PHER2 studie Naakte molrat nab-paclitaxel nab-paclitaxel plus gemcitabine NABON Breast Cancer Audit nachtarbeid NACT naevi NALA study nanoparticles nanotechnologie NAS nasofarynxcarcinoom nasopharyngeal cancer nasopharyngeal carcinoma National Breast and Cervical Cancer Early Detection Program National Cancer Data Base National Institute for Health and Care Excellence natriumthiosulfaat natural killer natural killer T-cel lymfoom NBTXR3 NC-6004 NCCN-richtlijnen NCGA NCGC NCI 8628 NCI-CONNECT NCI-Maryland Case Control Study NCI-Match Trial E131-Y NCI9673 NCIC CTG MA.27-studie NCM NCSLC NDMM NEC study NECC necitumumab negative colonoscopy negative for intraepithelial lesions or maligancy negative thyroid biopsy NELM NELSON-studie NEMO NENs neoadjuvant aspirine neoadjuvant bevacizumab neoadjuvant CAPOX plus radiotherapy neoadjuvant carboplatin plus docetaxel neoadjuvant chemoradiation neoadjuvant chemoradiotherapy neoadjuvant chemotherapy neoadjuvant durvalumab neoadjuvant erlotinib neoadjuvant FOLFIRINOX neoadjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel neoadjuvant gemcitabine plus S-1 neoadjuvant immune checkpoint blockade neoadjuvant lapatinib plus trastuzumab without chemotherapy neoadjuvant larotrectinib neoadjuvant nab-paclitaxel neoadjuvant pertuzumab neoadjuvant plus adjuvant erlotinib neoadjuvant radiotherapy neoadjuvant SABRT neoadjuvant therapy neoadjuvant trastuzumab emtansine plus pertuzumab neoadjuvante chemotherapie neoadjuvante CRT NeoALTTO NeoCombi study neonatal inflammatory markers neonatal phototherapy NeoPAL study NeoPalAna neoplasm risk neopterine nephrectomy nephrotoxicity neratinib nercelcarcinoom NET NETs neurale invasie neuro-endocrien carcinoom neuro-endocriene neoplasmen neuro-endocriene tumoren neuroblastoma neuroblastoom neurocognitie neurocognition neurocognitive function neuroendocrine prostate cancer neuroeondocriene tumoren neurofibromatose neurofibromatose 1 neurologic disorders neuropathie neuropsychiatric functioning neuropsychological outcomes neutrofiel lymfocyt-ratio neutrofiel-lymfocyt ratio neutropenie neutrophilia new treatment options newly diagnosed APL newly diagnosed cancer patients newly diagnosed endometrial cancer newly diagnosed multiple myeloma newly diagnosed or relapsed multiple myeloma newly diagnosed transplant-ineligible multiple myeloma next-generation sequencing next-generation sequencing of ctDNA NF1 NF2 NFκB NGS nHL NHL-001 study NHS NIBIT-MESO-1 studie nice-or-naughty theorie nicotine niercarcinoom niercelcarcinoom niercelkanker nierfunctie niet-cervicale anogenitale maligniteit niet-chirurgische behandeling niet-invasief prenataal testen niet-kelincellig longcarcinoom niet-kleincellg longcarcinoom niet-kleincellig longcarcinoom niet-kleincellige longkanker niet-melanoom huidkanker niet-seminomateus testiscarcinoom niet-squameus niet-kleincellig longcarcinoom nieuw logo Nieuw-Zeeland NIFTP night shift work NIH-AARP NIH-AARP Diet and Health study NIH-AARP Diet and Health Study; alcohol consumption NILM NiloPeg nilotinib nimotuzumab nintedanib NIPPON DATA 80 niraparib niraparib maintenance niraparib plus pembrolizumab nitraat nitriet nivolumab NIVOREN study NK NLCS NLPHL NLR nmCRPC NMIBC NMR NMSC NMSC-ASE NMSIs NNAL NO16968 NO2 NOA-07 studie NOCCA study nodal PTCL node-positive breast cancer nodulair lymfocyt-predominant Hodgkin lymfoom NOM non-alcoholic fatty liver disease non-germinal center B-cell DLBCL non-germinal center B-cell like diffuus grootcellig B-cel lymfoom non-Hodgkin lymfoom non-Hodgkin lymphoma non-inferioriteits fase 3-studie AXEPT non-melanoma skin cancer non-metastatic castration-resistant prostate cancer non-muscle-invasive bladder cancer non-relapse mortaliteit non-seminoom testikelkanker non-small cell lung cancer non-small cell lung cancer surgery non-specific symptoms and signs of cancer non-squamous metastatic non-small cell lung cancer nonadherence nonadherence to cancer screening nonaspirin NSAIDs noncancer mortality nongerminomatous malignant germ cell tumors noninferiority phase 3 study HYPO-RT-PC nonmelanoma skin cancer nonverbale communicatie Noorwegen NOPHO ALL2008 protocol NOPHO ALL2008 study NORCCAP-studie Nordic Lymphoma Group NORDIC9 study not transplant-eligilbe MM NOx NPC NPM1-gemuteerde AML NRAS-mutatie NRAS-mutaties NRG Oncology RTOG 1203 NRG Oncology RTOG studie 0621 NRG-GY003 NSABP B-28 studie NSABP B-31 study NSABP B-40 NSABP B-42 NSABP B-42 study NSAID NSAID-gebruik NSAIDs NSCLC NSCLC in postmenopausal women NSCLC with ALK or ROS1-rearrangement NSCLC; linifanib NSGCT NSM nsq-NSCLC NTD-Haplo versus SUCBT nucleaire installaties nuclear ZEB2 expression Nurses' Health Study Nurses’ Health Studies Nurses’ Health Study Nurses’ Health Study I and II Nurses’ Health Study II nursing home residents nut consumption nutrient intake NutriNet-Santé cohort NutriNet-Santé prospective cohort NutriNet-Santé studie NutriNet-Santé study nutritional status NWAS NWTS-5 OA-MCL OAC OAK OAK-studie obesitas obesitasparadox obesity obesity-related cancer trends obinutuzumab obinutuzumab plus lenalidomide Observationele studie van discontinueren van TKIs voor CML in de Italiaanse klinische praktijk OCC OCCC occult breast cancer occulte kanker occupational variation OCSCC ocular toxicity of bortezomib ODM-201 odontoom ODXRS oedeem oesofagaal squameus celcarcinoom oesofagastrische tumoren oesofagectomie oesofagogastrisch adenocarcinoom oesofagus squameus celcarcinoom oesofagusadenocarcinoom oesofaguscarcinoom oesofaguskanker oesophageal squmous cell carcinoma oestradiol oestrogeengebruik oestrogeenreceptor oestrogeensuppressie ofatumumab OGC OHERA study Okayama Lung Cancer Study Group Trial 1404 olanzapine olaparib olaparib maintenance olaparib plus cetuximab and IMRT older adults with cancer olfactorisch neuroblastoom oligometastase oligometastatic cancer oligometastatic cancers oligometastatic non-small cell lung cancer oligometastatic NSCLC OLIVIA OlympiAD-studie OM-CRC omacetaxine mepesuccinate omega 3-vetzuren OMEGA offspring cohort omission of dexamethasone oncolytisch adenovirus oncolytische virustherapie oncoplastische mammoplastie Oncoscience Oncotype Oncotype DX Oncotype DX DCIS-score ondergewicht onderhoudstherapie ondervoeding onderzoeksfraude one week off ONJ ONT-380 ontstaan colorectaalkanker ontwikkeling resistentie oogmelanoom Oost-Afrika OPAS-1 study OPC open resectie open versus minimally invasive surgery opioid use opioid use among older cancer survivors opleidingsniveau OPN OPSCC opsoclonus-myoclonus ataxie syndroom OPTIMA Prelim OPTIMISMM study optimizing chemotherapy OPTION-studie Opto-RTKs oraal carcinoom oraal oncogeen HPV oral arsenic trioxide oral cavity or oropharyngeal squamous cell carcinoma oral cavity squamous cell carcinoma oral endocrine therapy oral health oral hydration after cisplatin oral S-1 orale anticonceptiva orale contraceptiva ORCA-010 ORCHARRD orgaantransplantatie Organ transplant recipients organ-sparing transanal endoscopic microsurgery organic food consumption organische oplosmiddelen orgnnoïdencultures ORIENT-1 study orofaryngeaal squameus celcarcinoom orofarynx squameus celcarcinoom orofarynxcarcinoom oropharyngeal cancer orthopedische oncologie OS OS2006 Sarcome-09 study OSCC osimertinib OSJ Oslo 1-studie OSLO-COMET study osteonecrose van de kaak osteopenie osteopontin osteoporosis osteosarcoma osteosarcoom ototoxiciteit van chemotherapie OTX015 outcomes outcomes of surgery outcomes without locoregional treatment OV21 PETROC ovarian cancer ovarian function ovarian function suppression ovarian stimulation ovarian tumors ovariëctomie ovariumcacrinoom ovariumcarcinoom ovariumfunctie ovariumfunctie-suppressie ovariumfunctiesuppressie ovariumkanker ovariumtumoren ovariumvolume OVC overall survival overall survival-analyse van fase 3-studie ARCHER 1050 overdiagnose overdiagnosis overgewicht overhospitalisatie overlevers overlevers jeugdkanker overlevers kinderkanker overleving overleving borstkanker overleving CRC overleving in Europa overleving melanoom overleving oudere patiënten overweight oviductcarcinoom oxaliplatin oxaliplatine oxybutynin p16 Ki-67 dual stain and HPV16 18 genotyping p53 PABC PACE-studie pachymeningeal seeding PACIFIC-studie paclitaxel PACMEL trial PACT-15 studie PACT-19 study PADT Painyanitikul PALB2-mutatie PALB2-mutaties palbociclib palliatie palliatieve radiotherapie PALOMA-1 TRIO-18 PALOMA-2 analyse PALOMA-3 PALOMA-3 study PAMELA PAMELA-studie pan-RAF remmers PANACEA study pancreas pancreas cancer pancreas ductaal adenocarcinoom pancreas-adenocarcinoom pancreas-ductaaladenocarcinoom pancreas-MCNs pancreasadenocarcinoom pancreascarcinoom pancreaskanker pancreatectomie pancreatic cancer pancreatic cancer risk pancreatic cystic neoplasms pancreatic ductal adenocarcinoma pancreatic fistula pancreatic NETs pancreaticoduodenectomie pancreaticoduodenectomy PANFIRE panitumumab panobinostat PANVAC papillair craniofaryngioom papillair metastatisch niercelcarcinoom papillair schildkliercarcinoom paraganglioma paraneoplastisch neurologisch syndroom Parkinson PARP-remmer PARP1-expressie partial prostate treatment particpating in randomized breast cancer study PAs passief roken PASSOS Heart studie pathogenic germline variants pathogenic variants in less familiar cancer susceptibily genes pathologically node-negative neck patient reported outcome patient reported outcomes patient reported symptoms patient volume of oncologist patient- and clinican-reported patient-collected versus clinician-collected samples patiënt-gerapporteerde uitkomsten patient-reported outcomes patiëntnavigatie patients aged 40 years or younger patients younger than 50 years patterns of recurrence patterns of relapse after neoadjuvant chemotherapy in clinical practice PAVO study pazopanib pazopanib plus cetuximab PBC PBL PBSO PBT PC PCD PCI PCLO PCNSL PCOS pCR pCR to pertuzumab and trastuzumab PCSNL PD-(L)1-blockade PD-1 PD-1 Ab PD-1 and PD-L1 inhibitos PD-1 inhibitors for mNSCLC PD-1 PD-L1 inhibitors PD-1-inhibitor therapy PD-L1 PD-L1 expression PD-L1-positive advanced NSCLC PD-L1-positive mTNBC PDAC PDS PDT PEAK study pediatric acute leukemia pediatric ALL pediatric AML pediatric brain tumor survivors pediatric cerebral microbleeds pediatric CT-related radiation exposure pediatric hepatoblastoma pediatric locally advanced TRK fusion sarcomas pediatric low-grade glioma pediatric neuro-oncology pediatric posterior fossa tumors pediatric R R ALL pediatric relapsing high-risk ALL pediatric thyroid cancer incidence and mortality trends pediatrisch ALL pediatrisch AML pediatrisch ependymoom pediatrisch sarcoom pediatrische AML pediatrische CNS-tumoren pediatrische hersentumoren pediatrische leukemie pediatrische NETs pediatrische patiënt-gerapporteerde uitkomsten pediatrische stamceltransplantatie PEG PEG-IFN pegfilgastrim pegfilgrastim-profylaxe pegteograstim pelvic radiotherapy pelvic RT versus IMRT pembolizumab PEMBRO-RT study pembrolizumab pembrolizumab after locally ablative therapy pembrolizumab for advanced melanoma pembrolizumab for advanced NSCLC pembrolizumab for advanced prostate adenocarcinoma pembrolizumab for previously treated mTNBC pembrolizumab for previously untreated pembrolizumab plus axitinib pembrolizumab versus best supportive care for advanced HCC pemetrexed plus cisplatine penta-refractory MM peptide receptor radionuclide therapy percentage dense area perception of cancer risk percutaneous ablation PerELISA neoadjuvant study perfluarinated alkylated substances in serum perifeer T-cel lymfoom perifere neuropathie periodontale ziekte perioperative FLOT versus ECF ECX perioperative radiotherapy peripheral T-cell lymphoma peritoneal mesothelioma peritoneal metastases from gastric cancer peritoneale carcinomatose index peritoneale metastasen PERSEPHONE trial PERSIST-1 PERSIST-2 studie PERSIST-5 trial persistent postchemotherapy alopecia persistente pijn personalized ctDNA profiling PERTAIN study pertuzumab pertuzumab plus trastuzumab peru PERUSE study pesticide exposure PET PET CT PET-CT PET-CT staged localized follicular lymphoma PET-guided risk adapted treatment PETAL-studie peulvruchten pevonedistat pexidartinib PF-05280014 PFS PFT PGC-1α PGF PGHD PGT Ph- ALL Ph-ALL Ph-like ALL Ph-negative ALL in older patients Ph+ ALL phase 2 BENEFIT trial phase 2 study JULIET phase 3 KEYNOTE-062 study phase 3 NEJ026 study phase 3 study AML08 phase 3 study COMBI-AD phase 3 study TRAIN-2 phase 3 study TRIBE 2 phase 3 trial RADAR phase III POLO trial Phc pheochrmocytoma PHEREXA-studie Philadelphia chromosome-negative ALL PHILEMON-studie PHOENIX study PHP-Mel physical activity physical activity during adolescence physican workforce requirements PI3K mTOR-remming PI3K-signalering PI3Kδ PIB PICN pictilisib pigmented skin lesion classification pijnlijke botmetastasen PIK3CA PIK3CA-altered HNSCC PIK3CA-mutaties pilaralisib pilocarpine pimecrolimus pioglitazon pituitary macroadenomas PIVOT-studie pixatimod plus nivolumab PL placebo adverse events in cancer trials PLACOL-studie plasma-based genotyping plasma-biomarkers plasmacarotenoïden platinum-resistant ovarian cancer platinum-resistente ovariumkanker PLATO study plaveiselcelcarcinoom PLCO cancer screening trial pleiomorf lobulair mammacarcinoom pleister pleural mesothelioma pleurectomie pleurectomy decortication PLGA PLGG ploegendienst PLP PLR PLRG Observational Study PM PMF PMRT PN pnacreascarcinoom pNET pneumonitis PO-IMRT versus PPLN-IMRT POEMS final analysis Poland polatuzumab vedotin POLE-mutaties POLLUX-studie POLO study polo-like kinaseremmer poly-G repeats polycyclische aromatische koolwaterstoffen polycystische nierziekte polycythemia vera polyfarmacie polymerase theta polymorfismen polypectomie polypharmacy polypose pom-dex pomalidomide ponatinib population-level survival PORT PORTEC-3 PORTOS POSH-studie positive initial margins positive margins post hoc analyse ASPIRE-studie post hoc analyse FIRST-studie post hoc analyse KEYNOTE-001 studie post hoc exploratieve analyse RAISE-studie post-hoc analyse PETACC-8 studie post-hoc analyse REACH-studie post-mastectomie radiotherapie post-progression outcomes post-transplantie lymfoproliferatieve ziekte postdiagnostic calcium intake postembolization syndrome postmastectomy radiotherapy postmenopausal advanced HR-positive breast cancer postmenopausal bleeding postmenopausal breast cancer postmenopausal CRC risk postmenopausal women postmenopauzaal mammacarcinoom postmenopauzaal mammarcinoom postmenopauzale borstkanker postmenopauzale hormoontherapie postmenopauzale vrouwen postoperatieve mortaliteit postoperative mortality postoperative radiation field postoperative seizures postoperative SRS postoperative surveillance posttraumatische stressstoornis poziotinib PPAR-gamma PPIs PR-status PR1 PRACTICAL-studie PrCa PRCC pre-BCS MRI pre-leukemisch PRECIS study precisie-oncologie precisietherapie precision medicine PRECISION-studie prediabetes prediagnostic telomere length PREDICT prediction of AML risk in healthy individuals prediction of outcome prediction of progression predictions for 2019 predictive role of frameshift mutations predictive value of SNP-signature for recurrence predictors of outcome of HCT predictors of recurrence predictors of survival preëclampsie preexisting antibodies preexisting pain PREF ALL pregabalin pregnancy pregnancy after cancer diagnosis pregnancy-associated breast cancer pregnancy-associated cancer prehabilitatie prehabilitation preïmplantatie-genetische diagnose premature menopauze premenopausal breast cancer risk prenatale blootstelling prenatale carcinogenenblootstelling preoperatieve chemotherapie preoperatieve MRI preoperatieve radiotherapie preoperatieve radiotherapie voor rectumkanker preoperative adverse event risk index for head and neck cancer surgery preoperative anemia preoperative elevated tumor markers preoperative embolization preoperative MRI preoperative PET CT preoperative risk evaluation Preoperative-Palbociclib studie PREVAIL-studie prevalence of clinical diagnosis of ADHD prevalence of HBV preventie preventie cervixkanker preventie mammacarcinoom prevention of early menopause preventive drugs in the last year of life previously treated advanced cervical cancer previously treated advanced NSCLC previously treated small-cell lung cancer previously untreated AML prijzen medicatie primair CNS-lymfoom primair melanoom primair urethracarcinoom primaire borstkanker primaire plasmacelleukemie primary breast cancer treatment primary care clinic appointment time primary CNS lymphoma primary debulking surgery primary surgery primary tumor location primary versus acquired T790M mutatiion PRIME study PRINCIPAL study PRO-CTCAE PRO-IMPACT studie PRODIGE 20-studie PRODRIGE18 study PROFILE 1001 study ProfiLER-studie PROFILES registry profylactische mastectomie prognose prognose luminal A prognosis prognostic case volume thresholds prognostic factors prognostic implications prognostic index prognostic model prognostic protein-based signature prognostic risk score prognostic role in lung cancer prognostic role of circulating cell-free DNA prognostic role of hypoxia and angiogenesis prognostic value of CTCs prognostic value of TILs prognostication prognostische biomarker prognostische discordantie prognostische test prognostische tools mammacarcinoom progressievrije overleving progressievrije overleving na 24 maanden progression risk stratification progressive MPM projections until 2030 prolaris prolonged infusion of low dose gemcitabine PROMIS-studie PROMISE-studie promotie PRONOPALL-studie PROPHECY study prophylactic chestwall irradiation prophylactic contralateral breast irradiation prophylactic cranial irradiation PROREPAIR-B study PROs PROSELICA-studie Prosigna Prosigna risk of recurrence score prospective genotyping prospective validation Gail Model PROSPER study prostaatcarcinoom prostaatcarcinoom. androgeendeprivatietherapie prostaatkanke prostaatkanker prostaatkankermortaliteit Prostaid prostate cancer prostate cancer aggressiveness prostate cancer mortality prostate cancer progression prostate cancer risk prostate cancer risk and mortality prostate cancer treatments prostate cancer; long-term follow up NRG RTOG 9413 study prostatectomie proteasome inhibitor proteasoomremmer ProtecT PROTECT-1 en -2 studies PROTECT-studie proton beam radiotherapy proton therapy protonradiotherapie protontherapie proximal colon serrated neoplasia proximal versus distal detection PRT PS PSA PSA bounce PSA-recidief PSA-screening PSAD PSCCB pSmad2 psychiatric utilisation prior to cancer diagnosis psycho-oncology psychological distress PTBP1 PTC PTCL pten PTEN-verlies PTGS2 PTH PTSD pulmonaire metastasen pulmonary fibrosis purchase of antidepressants PURE-01 study PUVA therapy PV PVRL pyrotinib pyrotinib plus capecitabine Q-koorts QNBC QoL QSkin-studie QUADRA study quality of life quality-adjusted time without symptoms of progression or toxicity QuANTUM-R study QuiRedex quizartinib R M ACC R R AML R R AML MDS R R cHL R R CLL R R DLBCL R R folliculair B-cell lymphoma R R FTL3-mutated AML R R HL R R MM R R MZL r r-AML R-cadherine R-CHOP R-CHOP 14 versus 21 studie R-CHOP-14 R2-CHOP RAAS race and risk of subsequent aggressive breast cancer race and survival race-based differences in survival radcial cystectomy RADIANT-2 RADIANT-4 radiation to hypothalamus and pituitary radiation-associated intracranial malignancy radiation-induced cardiac toxicity radical hemi-thoracic radiotherapy radical prostatectomy versus watchful waiting RADiChol-studie radioactief jodium radioembolisatie radiofrequency localization radiofrequentie-ablatie radiogenomics radiojodium-refractair gedifferentieerd schildkliercarcinoom radiologic complete response radiomica radiomics radionecrosis radiosurgery radiotherapie radiotherapy radiotherapy-related heuropathic pain radium 223 radium-223 radon RAI for hyperthyroidism RAINBOW-studie RAINFALL study raloxifeen ramucirumab RANGE-studie rare cancers rare CNS tumors rare versus common genetic variants RARECAREnet RAS wildtype metastatic colorectal cancer RAS-mutaties RASTEN-studie rate of memory change RCC RCM RD re-excisie re-testing predictive biomarkers in surgical specimens REACH-2 study readministration of anti-PD-1 or anti-PD-L1 after irAE readmission real world outcomes real-world outcomes real-world survival real-world treatment and survival rEC receptorstatusverandering recidief recidiefrisico recidiefrisico ER-positief mammacarcinoom recidiverend multipel myeloom recidiverend of refractair ALL recidiverend of refractair mantelcellymfoom recidiverend of refractair multipel myeloom recidiverend refractair mantelcellymfoom recidiverend refractair multipel myeloom recidiverend refractair PCNSL recidiverende beroerte recidiverende ER-positieve borstkanker RECIST recombinant poliovirus for recurrent glioblastoma recombinant zoster vaccine RECORD-2 recovery of ovarian function rectal cancer rectal cancer in elderly patients rectumcarcinoom rectumccarcinoom rectumkanker recurrence recurrence patterns after RT for brain metastases recurrent acute myeloid leukemia recurrent advanced urothelial cancer recurrent GBM recurrent glioblastoma recurrent glioma recurrent high grade glioma recurrent high-grade serous ovarian cancer recurrent metastatic breast cancer recurrent of refractory soldi tumors in children and adolescents recurrent or metastatic HNSCC recurrent platinum-resistant ovarian carcinoma recurring endometrial cancer ReDOS study reduced LVEF reduced-dose fluoropyrimidine therapy refractory large B-cell lymphoma refusal of conventional cancer therapy refusal of surgery regional lymph node irradiation regionale lymfeklierbestraling REGOBONE study REGOMA study regorafenib REGOSARC rejection of systemic therapy relapse relapse after allogeneic stem-cell transplantation relapse after autoSCT relapse detection by routine CT scan versus symptoms relapsed CLL relapsed CLL SLL relapsed follicular lymphoma relapsed glioblastoma relapsed multiple myeloma relapsed or refractory classical Hodgkin lymphoma relapsed or refractory indolent lymphoma relapsed or refractory multiple myeloma relapsed or refractory non-Hodgkin lymphoma relapsed or refractory primary CNS or introcular lymphoma relapsed platinum-sensitive ovarian cancer relapsed refractory Hodgkin lymphoma relapsed refractory multiple myeloma relapsed refractory NHL relative dose intensity relative lymphocyte count RELAZA2 study RELEVANCE trial religieuze overtuigingen REMAGUS02 study remaining life expectancy remming CD95-route remming hedgehog-signaalroute remnant liver ischemia REMOTUX trial renal cell carcinoma RENO study reovirus RERISE-studie resectable lung SCC resected ampullary carcinoma resected biliary tract cancer resected brain metastases resected colorectal liver metastases resectie laaggradig glioom resection resection before immunotherapy resection of brain metastases residual HER2-positive breast cancer resiquimod resistant starch resistentie RESONATE study RESONATE-17 respiratory morbidity respiratory outcomes Response Assessment in Neuro-Oncology werkgroep response to HER2-targeted therapy response to lung cancer immunochemotherapy response to stereotactic radiosurgery RESPONSE-2 RESTORE Restoring Invisible and Abandoned Trials results in North America resumption of immune checkpoint inhibitor therapy Ret RET-fusion positive NSCLC RET-rearranged lung cancer retinoblastoom retinol retroperitoneaal sarcoom retroperitoneal liposarcoma retroperitoneal lymph node dissection retroperitoneal sarcoma retrospectieve analyse PETACC-3 studie reumatoïde artritis REVERCE study reverse gene expression profiling RFA rhabdomyosarcoma rhabdomyosarcoom riboflavine RIC alloHSCT rich TILs Richter transformation RICMAC-studie ridaforolimus rilotumumab RILT rindopepimut risedronaat risico borstkanker risicoscore risicostratificatie risk factors for progression risk of all cancer types risk of cancer risk of cardiovascular hospitalization risk of colorectal adenoma risk of glioma risk of internal malignancies risk of lethal prostate cancer risk of lung risk of malignant neoplasms risk of preterm birth risk of progression risk of second event after DCIS risk of secondary malignancies risk of SMNs after treatment for testicular germ cell cancer risk of subsequent cancers risk of suicide risk of suicide after cancer diagnosis risk of testicular germ cell tumors risk prediction model risk-reducing salpingo-oophorectomy rituximab rituximab maintenance rituximab plus lenalidomide rituximab SC of IV rivaroxaban RMM RMP RNA-disruptie RNU2-1f ROAR basket trial robot-geassisteerde prostatectomie rociletinib roken rolapitant ROLARR-studie ROMANA 3-studie romidepsine ROMULUS study rookloze tabaksproducten ROS-1 rearranged NSCLC ROS1-rearranged advanced NSLCL ROSE TRIO-012 Ross rotating night shift work Rotterdam Study Rova-T RP-LPS RPD vs OPD rPFS RPLMS RPS RR CLL SLL rrHL RRMM rrPMBCL RRSO RRx-001 rs4143094 RT RT after complete response to ABVD RT plus XRT RTOG 0126-studie RTOG 0214 study RTOG 0521 study RTOG 0617 RTOG 0813 trial RTOG 1016 study RTOG-0129 risk groups RTSG-SIOP RTW rucaparib maintenance ruxolitinib ruxolitinib plus azacytidine S-1 S-TRAC trial S1P-antagonisme SA SABCS 2015 SABR SABR-COMET study SABRINA-studie sacher sacituzumab govitecan sacituzumab govitecan-hziy SACURA trial SAFE-HEaRt study safety of AA with glucocorticoids safety of CRS HIPEC SaGa SAKK 35 10 trial sALCL salivary MECs salpingectomie SALTO-studie salvage chirurgie salvage re-irradiation salvage treatment salvage treatments sAML saracatinib SARAH-studie SARC024 study SARC028-studie sarcoma sarcomatoid HCC sarcoom sarcopenia sarcopenic patients sASCT sAxl SBA SBM SBRT SBRT schedule SC SC.23 scalp cooling scalpmelanoom Scandinavian HYPO-RT-PC study SCC SCCA SCCAC SCCHN SCCOT SCCUP sCD23 schade kleine hersenvaten schildkliercarcinoom schildklierkanker schildkliertumoren schildwachtklier schildwachtklierbiopsie schildwachtlymfeklierbiopsie SCIENTIFIC-studie SCLC SCORAD III-studie SCOT-studie screen-detected vs non-screen-detected screening screening cervixcarcinoom screening colorectaalcarcinoom screening contralateraal mammacarcinoom screening CRC tumors for Lynch syndrome screening digital mammography screening longcarcinoom screening mammacarcinoom screening ordering and completion SCSHN SDF1 SEAFOOD Polyp Prevention Trial SEAL second allo-HCT versus donor lymphocyte infusion second cancers after radical treatment second line FOLFIRI plus ramucirumab second primary cancers second primary NSCLC after HNC second solid cancer outcomes second-line binimetinib plus capecitabine second-line XELIRI versus irinotecan monotherapy secondary analysis CONVERT study secondary analysis of CheckMate 141 secondary MDS AML secondary solid tumor malignancies secundaire analyse ATAC-studie secundaire analyse AZURE-studie secundaire analyse BIG 1-98 studie secundaire analyse GOG-0218 studie secundaire analyse GOG-210 studie secundaire analyse LUX-Lung 8-studie Secundaire analyse NSABP B-30 Secundaire analyse REVEL-studie secundaire analyse van CANTOS-studie Secundaire analyse van EF-14 secundaire analyse van EORTC 22952-26001 secundaire analyse van FAPEST-studie secundaire analyse van GeparSixto secundaire analyse van GOG-0218 studie secundaire analyse van RTOG 9704-studie secundaire analyse van STO-3 studie Secundaire analyse van SWOG S0221 sedentaire tijd segmentectomie SEHIB-studie SEIPLUS study seksueel functioneren seksuele toxiciteit SELECT trial SELECT-1 studie SELECT-D studie selecteren van moleculair-geleide therapie selectieve interne radiotherapie seleen Selenium and Celecoxib Trial self-compression versus standard compression SELHEM selinexor selumetinib seminoom SEMS SenSzi study sentinel sentinel lymph node biopsy sentinel-node micrometastases sepantronium bromide sEpCAM sequencing plasma cell-free DNA sequential ICI and crizotinib sequential PD-(L)1 blockade and osimertinib sereus ovariumcarcinoom serial imaging SERM Sertoli-Leydig serum assessment of non-adherence serum proteomics serum thiol levels serum VEGF serum vitamin E serum-metaboloomprofiel serum-microRNAs serumlipidem serumlipiden SES sex difference sex differences in prognosis sex-based heterogeneity sex-linked differences sexually transmitted infections Sézary syndrome Sézary syndroom SGC shared decision making SHCC short regimen of rituximab plus lenalidomide Short-HER study short-term mortality after starting chemotherapy SHR-1210 SI-NETs SIA sidedness sigaren siglec sigmoidoscopy screening signifor siltuximab silver jk simian virus 40 SIMONAL study SIMPLICITY-studie SIMPLIFY-1 studie Singapore Chinese Health Study single dose HDR brachytherapy single versus multiple primary melanomas single-fraction SBRT vs multifraction conventional RT sinonasaal adenocarcinoom sinonasaal carcinoom sinonasaal melanoom sintilimab sirolimus SIRveNIB-studie Sister Study Sisters Study sites and sequence of metastases six versus 12 months adjuvant capecitabine skelet-gerelateerde gebeurtenissen skeletal metastases skeletal muscle loss skin cancer skin cancer prevention skin cancer risk skull-base chondrosarcoma slaapduur sleep characteristics SLL SLN-biopsie SLN-status SLNB slokdarm adenocarcinoom slokdarm squameus celcarcinoom slokdarmadenocarcinoom slokdarmcarcinoom slokdarmkanker slokdarmkanker; chemoradiotherapie SM SMAD4 loss small lymphocytic lymphoma small node-negative HER2-positive breast cancer small-cell lung cancer smeulend multipel myeloom SMM SMN SMNs smoking smoking cessation smoldering multiple myeloma SNIPP study snoRNAs SNP SNPs SNPs correlated with sunitinib benefit SNTI SNUC SOAR-studie sociaal-economische status Sociaaleconomische status sociale media soft tissue sarcoma SOFT- en TEXT-studies soft-tissue sarcoma sojaconsumptie SOLAR-1 study SOLD-studie SOLE-studie solid cancer diagnosis solid organ transplant solid-organ transplant solide maligniteiten solide tumoren solitair intrathyroïdaal papillair schildkliercarcinoom solitary fibrous tumor solitary pulmonary nodules SOLO1 study SOLO2 ENGOT-Ov21 studie somatische variatie somatostatin analogues somatostatine-analogen sorafenib sorafenib for advanced HCC sorafnib maintenance after allo-transplantion SORAML SORMAIN Trial SOS-studie sotatercept SOX2 soy-based dietary supplements SPARC SPARTAN-studie SPC SPCG-4 special section of Supportive Care in Cancer spectroscopie sperm count Spierinvasief blaascarcinoom spinaal myxopapillair ependymoom spinal metastases spinal metastatic disease spinale epidurale metastase spinale metastase spinale SRS SPIONs splanchnische veneuze trombose splenisch DLBCL splicing factor SPMN SPMs spontane abortus sporadic colorectal cancer spread through air spaces SPS sputum miRNA sqCLC squameus celcarcinoom squameus celcarcinoom van de mondholte squameus celcarcinoom van de orofarynx squameus celcarcinoom van hoofd en hals squameus-celcarcinoom squamous cell carcinoma squamous cell carcinoma of head and neck squamous NSCLC SQUIRE-studie SRCC SRE SREs SRS SRT SRT versus ART SS SSIs SSTR2 St Jude Lifetime Cohort Study St. Jude Lifetime Cohort stadium IV colorectaalcarcinoom stadium IV-NSCLC stage 0 to II breast cancer stage 1 nonseminomatous GCTs stage 1 NSCLC stage 1A RCC stage 2 colorectal cancer stage and grade I endometrioid endometrial cancer stage at cancer diagnosis stage I breast cancer in women 65 years and over stage I NSCLC stage I-II cutaneous melanoma stage II colon cancer stage II III gastric cancer stage II III rectal cancer stage II-IIIA NSCLC stage III colon cancer stage III gastric cancer stage III inflammatory breast cancer stage III NSCLC stage III ovarian cancer stage IIIA NSCLC stage IIIA-N2 EGFR mutation-positive NSCLC stage IIIB and IIIC melanoma stage IIIB-C BRAF-V600 mutated melanoma stage IV ALK rearranged NSCLC stage IV breast cancer stage IV breast cancer at diagnosis stage IV TNBC staged stereotactic radiosurgery stamceltransplantatie STAMPEDE STAMPEDE study standard-risk NDMM stappenteller START statin use statines statins statistieken 2012 statistische genezing stemmingsaandoeningen stereotactic ablative radiotherapy stereotactic body radiation therapy stereotactic body radiotherapy stereotactic radiosurgery stereotactic RT versus WBRT for cystic or solid brain metastases stereotactische lichaamsradiotherapie stereotactische radiochirurgie stereotactische radiotherapie sterfte aan kanker steroid refractory GVHD in children sTILs Stockholm III stoma stomach cancer pooling project stomatitis Stop & Go study STOP IMAPED study stopping imatinib STORM Study part 2 straling STREAM-studie stroma-gerichte therapie stromal tumor-infiltrating lymphocytes stromale tumor-infiltrerende lymfocyten STS STSs Studie-uitval Study 19 STZ 5-FU subcutaan trastuzumab subcutaneous administration of daratumumab subcutaneous versus intravenous PF-06801591 subcutaneous versus intravenous trastuzumab subependymal giant cell astrocytoma subgroep-analyse van METEOR-studie subgroepanalyse ALEX-studie subgroepanalyse GREEN study subgroepanalyse MONALEESA-2 studie subgroepanalyse van FIRE-3 studie subgroepanalyses LUX-Lung studies subgroepenanalyses CAIRO3 sublobar resection subsequent primary neoplasms substratification substudie ALTTO substudie van TRYPHAENA subtotal resection subtype subtype-specific CBC subtypen subtypen HER2-positieve borstkanker subtypes subtypes maagcarcinoom subtypes mammacarcinoom SUCCESS A SUCCESS A trial SUCCESS-C study sugary drink consumption and risk of cancer suïcide sun exposure suncreen use sunitinib sunitinib dose and schedule optimization sunitinib for RCC SUNSHINE trial superficial basal-cell carcinoma superior vena cava syndrome suppressie ovariumfunctie supraglottische-larynxcarcinoom SUPREMO trial surgery surgery for head and neck cancer surgery for non-palpable breast lesions surgery versus active surveillance surgical excision margin surgical treatment surgically treated brain metastases surival surrogate end points SURTIME trial surveillance surveillance colonoscopy after advanced adenoma removal surveillance for relapse survival survival after radiotherapy survival after recurrence survival in breast cancer survival of advanced NSCLC survival trends survivin-expressie survivors AYA cancer survivors childhood ALL survivors childhood and AYA cancer survivors of childhood and AYA cancer survivors of childhood cancer survivors of childhood Hodgkin lymphoma survivors of HPV-associated cancers survivors of non-central nervous system tumors in childhood survivors of pediatric CNS tumors susceptibility gene mutations SVCS SVT SWAN-studie Swedish Breast Cancer Group 91 Radiotherapy studie Swedish Multicenter Cohort Study SWISH-studie SWITCH SWOG 0777 SWOG 1200-studie SWOG 1406 SWOG 80405 SWOG S0337-studie SWOG S0518 SWOG S0622 SWOG S0800 SWOG S1202-studie SWOG-S0016 SWORD-studie Sym004 symptomatic osteonecrosis synchronous and lifetime brain metastases synchronous bilateral breast cancer synchronous stage IV anal canal squamous cell carcinoma synoviaal sarcoom synoviosarcoom systemic treatment systemische lupus erythematosus systemische mastocytose SystHER study t-APL T-cadherin T-cel acute lymfoblastische leukemie T-cel lymfoom T-cell lymphoblastic lymphoma T-cellymfoom T-DM1 T-VEC T1-T2 RCC TABEA TAC TACE tagraxofusp TAGS study TAILOR trial TAILORx analysis TAILORx study TAILORx-studie talazoparib talk-pleurodesie tamilogene laherparepvec tAML tamoxifen TAPS TARDOX study targeted agents targeted alpha therapy targeted exome next-generation sequencing targeted intraoperative radiotherapy targeted therapies targeted therapy targeted versus nontargeted therapy targeting long-term non-attenders TAS-102 TAS-114 TATTON study Taxaan resistentie taxane chemotherapy TAXYNERGY-studie TAZ TBCRC 022 study TBCRC026 study TBISI TC TCF3-HLF positief ALL TCH tea intake TEAM IIB TEAM-studie Teenage and Young Adult Cancer Survivor Study tele-oncologie telemedicine televisiekijken telisotuzumab vedotin telomeerlengte telomeerziekten telomerase-activiteit temozolomide temporal muscle thickness temporal trends temsirolimus ten-year results tenofovir tenosynovial giant cell tumor tenosynovial giant-cell tumor teratoma terbinafine TERRA-studie TERT-mutatie testicular cancer testicular cancer in children and young adults testicular germ cell tumors testikelkanker testiscarcinoom textbook outcomes of curative-intent resection TFAP2C tFL TG4010 TGCT TGF-βRII TH-302 TH3RESA thalidomide The Multiethnic Cohort thee therapeutic options therapeutische vaccins therapietrouw orale hormonale behandelingen therapy-related AML therapy-related cardiac risk thermal ablation thermal ablation versus nephrectomy thermale ablatie thick melanoma Thinking and Living With Cancer Study thiopurine thiotepa-busulfan-fludarabine conditioning thorax-radiotherapie thromboprofylaxis thrombosis thrombotic events THRα2 thymoom thymuscarcinoom thyroid cancer thyroid nodules Tian TIC TIL therapy TILs time between positive gFOBT and colonoscopy time interval to biochemical failure time series analysis time to death time to metastasis time to treatment failure time-to-surgery timing of HPV16-E6 antibody seroconversion timing of local therapy timing of onset of irAEs tinzaparine TIPN tirlateraal retinoblastoom tisagenlecleucel tisotumab vedotin TITAN study TITAN-studie TKI TKI discontinuation TKIs TL TMB TMNs TMW TMZ tnAcity-studie TNBC TNBC risk genes TNFi TNFα-remmers TNT-studie TOAD-studie tomaten tomosynthese tomosynthesi tongbasiscarcinomen tonsilcarcinoom tonsillaire topisch fluorouracil toripalimab TORS totaal lichaamsbestraling totaal-vet total neoadjuvant therapy totale lichaamsbestraling totale mesorectale excisie totale mortaliteit totale overleving TOURMALINE-MM3 study toxiciteiten van oncologische behandelingen toxicity-related chemotherapy modifcation TP53 TP53 mutation status TP53-mutaties TP53-veranderingen TPK cohort TPP traankliertumoren trabectedin trabectedin plus radiotherapy TRACERx trametinib tranplantation-ineligible MCL patients transarterial chemoembolization transarterial hepatic chemoembolization transarteriële chemo-embolisatie transdermaal fentanyl transdermale toediening transformation transformation to SCLC transgender people transgenders transorale robotische chirurgie transplant-ineligible multiple myeloma TRASTS study trastuzumab trastuzumab deruxtecan trastuzumab duocarmazine trastuzumab emtansine trastuzumab plus paclitaxel trastuzumab-resistant HER2-positive breast cancer treatment treatment at specialized cancer centers treatment failure treatment interruption treatment recommendations treatment-emergent small-cell neuroendocrine prostate cancer treatment-related cardiotoxicity treatment-related incidence of diseases of the circulatory system treatment-related toxicity treatments for advanced NSCLC trebananib tremelimumab TREnd-studie trends trends 2005-2015 trends 2008-2014 trends of cancer in children and adolescents trial effect TRIAS study TRIBE TRICOLORE-studie trimodal therapy TRINOVA-1 triple negatieve borstkanker triple negative borstkanker triple negative breast cancer triple negative mammacarcinoom triple-negatief mammacarcinoom triple-negative borstkanker triple-negative breast cancer triple-negative mammacarcinoom triptorelin TROG 03.01-studie TROG 99.03 study trombo-embolie trombocyt lymfocyt ratio TRT TSC TSCC Tsjernobyl TSP-1 TSR TTAC TTC TTF TTFields TTP tubaligatie Tubo-ovarian high-grade serous carcinoma tubulysines tucatinib tucidinostat tumor budding tumor mutation burden tumor mutational burden tumor regrowth between surgery and radiotherapy tumor suppressor tumor treating fields therapy tumor-DNA tumor-geassocieerde neutrofielen tumor-immuuntolerantie tumor-infiltrating lymphocytes tumor-stroma ratio TUMORAPA study tumorgraad tumorgrootte tumorinfiltrerende lymfocyten tumoronderdrukkers tumorpredispositiesyndroom tumorsubtypen tv kijken TVU tweede kanker tweede maligne neoplasmen tweede maligniteit tweede mammacarcinoom tweede primaire maligniteit tweejaaars-overleving tweevoudige HER2-blokkade twice versus once daily radiotherapy for SCLC two weeks on type 1-diabetes type 2 diabetes tyrosinekinaseremmers tyrosyl-DNA fosfodiësterase 1 UADT-carcinomen UATD-kanker UBC UC UCB UCC UDON UGT1A1 genotype uHCC UIP-ADC UK Flexible Sigmoidoscopy Screening Trial UK IMPORT LOW studie UK Million Women Study UK MRC OE05-studie ultrasonografie ultrasonography ultrasonography findings ultrasound umbralisib umbrella protocol UMRD underestimation of invasive breast cancer United Kingdom Women’s Cohort Study UNITY-NHL study unknown primary lesions unmet needs unnecerssary adjuvant chemotherapy in breast cancer unplanned 30-day readmission unplanned reoperation unrelated donor hematopoïetische celtransplantatie untreated multiple myeloma uPAR update MONALEESA-2 Update WECARE-studie updated analysis KEYNOTE-024 upper tract urothelial cancer upper tract urothelial carcinoma upper-tract urothelial carcinoma urbanisatiegraad urinaire bijwerkingen urinary cytokine profile to predict response urine DNA hypermethylation signatures urine tumor DNA urinetest urineweginfectie urotheelcarcinoom urotheelcarcinoom van de blaas urotheliaal blaascarcinoom urotheliaal carcinoom urothelial bladder carcinoma urothelial cancer diagnosis USC use of BRCA-testing use of fertility drugs uterine corpus cancer incidence and survival trends uterine leiomyosarcoma uteruscarcinoom UTUC uveaal melanoom uveaalmelanoom V600E V600K BRAF-mutant melanoma vaccin vaccin mammacarcinoom vaccinatie vaginal brachytherapy plus chemotherapy VAIN Val600 BRAF-mutant melanoom validation VALOR-studie valproaat vals positieve uitslag varying test positivity thresholds Vasaloppet vasectomie vasectomy VCE VE-BASKET study veeleisende patiënten vegetarische voeding VEGF VEGF-behandeling VEGFR-remmer VEGFR-TKI VEGFR-TKIs VELVET VELVET cohort 2 vemurafenib vemurafenib plus everolimus venetoclax venetoclax plus low-dose cytarabine venetoclax-BR veneuze trombo-embolie venous thromboembolism verbal memory verf verhoogd bloedglucose VeriStrat test vermoeidheid verpleegkundigen verteerbaar koolhydraat vertrouwen verzadigd vet vessel co-option vestibular schwannoma vetinname vetrijke voeding vetzuren VGX-3100 video-assisted thoracoscopic surgery VIN vincristine vinorelbine VIOLA study virotherapy viscerale adipositas visconsumptie VITAL study VITAL-studie vitamin D vitamin D binding protein vitamin D levels vitamin D supplement use vitamin D3 vitamin K antagonists vitamin supplements vitamine B3 vitamine B6 vitamine D vitamine D-spiegel vitamine-inname vitiligo Vivio VIVROVAIRE I study VLADI-studie Vlagtwegge-Vlaardingen cohort vlees vleesconsumptie vliegend personeel vluchtige organische verbindingen VMS VOCs voeding voeding tijdens zwangerschap voedingsgewoonten voedingskwaliteit voedingssupplementen voedingsvezel volasertib volatile organic compounds VOLFI-studie von gunten von hippel-lindau Von Willebrand Disease voorspelling recidief voorspelling ziektevrije overleving vosaroxine VR consolidation vroeg mammacarcinoom vroege detectie vroege detectie MBC vroege menopauze vroege resultaten COMPASS-studie VS VSCC VTE VTEs vulvacarcinoom vulvaire intra-epitheliale neoplasie vulvaire intraepitheliale neoplasie vulvaire lichen sclerosus VWF wachttijd Waldenström macroglobulinemia Waldenstrom's macroglobulinemie Waldenström’s macroglobulinemie warfarine warren watch and wait watch-and-wait watchful waiting WBI WBM WBRT WD DDLS WDTC web-based symptom monitoring vs routine surveillance WECARE-studie weefseltype-agnostische gerichte therapie weekly carboplatin and paclitaxel weekly KMP weekly paclitaxel weight cycling weight loss wekedelensarcoom wekedelensarcoom. STS werkloosheid werkzaamheid placebo WES wetenschappelijk wangedrag WHI WHI-CaD studie WHI-DM whole brain radiotherapy whole-body MRI whole-brain radiation therapy whole-genome sequencing WHR wigresectie Wilms tumor Wilms' tumor Wilms’ tumor withdrawal of antiepileptics WM women's health initiative Women's Health Initiative-Observational Study Women’s Health Initiative WSG-ADAPT studie WT WTB-HRM WTC-responders XELAVIRI study XELOX FOLFOX vs LV 5-FU xerostomia XRT plus ADT YAP YKL-40 YM155 yoga yogurt consumption young adult ALL patients ZAP-studie zegelringcelcarcinoom zelf-gerapporteerde vermoeidheid zelf-onderzoek huid zelf-test ziekenhuisvolume Ziekte van Castleman Ziektevrije-overlevingsanalyse van ABCSG-18 studie zinc-α2-glycoprotein zittende leefstijl ziv-aflibercept zoledroninezuur zonlicht ZUMA-1 studie ZUMA-1 trial ZUMA-studie ZW25 zwangerschap zwangerschaps-geassocieerd mammacarcinoom zwangerschapsuitkomsten γ-glutamyltransferase